



HOUSE BILL No. 1005

DIGEST OF HB 1005 (Updated January 29, 2020 3:03 pm - DI 77)

Citations Affected: IC 5-14; IC 12-26; IC 16-18; IC 16-21; IC 16-24.5; IC 16-47; IC 16-51; IC 25-22.5; IC 25-26; IC 27-1; IC 27-2; IC 27-4; IC 27-8; IC 27-13; IC 36-2.

Synopsis: Health and insurance matters. Establishes the importation of prescription drugs program (program) for the importation of prescription drugs to be administered by the state department of health (state department). Requires the state department to apply to the federal government for approval of the program. Sets forth requirements for the vendor of the program. Sets requirements for suppliers, importers, and wholesale drug distributors of the program. Requires the state department to submit reports to the governor and the general assembly concerning the program. Establishes for participants in the program an international export pharmacy permit and wholesale drug distributor permit administered by the Indiana board of pharmacy. Provides that a facility is an off-campus location of a hospital if: (1) the operations of the facility are directly or indirectly owned or controlled by, or affiliated with, the hospital; (2) the facility provides services that are organizationally and functionally integrated with the services of the hospital; and (3) the facility provides preventive services, diagnostic services, treatment services, or emergency services. Requires hospitals, ambulatory surgical outpatient centers, and urgent care facilities to post certain health care services pricing information by billing code on the (Continued next page)

Effective: Upon passage; July 1, 2020; January 1, 2021.

Schaibley, Lehman, Carbaugh, Shackleford

January 6, 2020, read first time and referred to Committee on Public Health. January 23, 2020, amended, reported — Do Pass. January 29, 2020, read second time, amended, ordered engrossed.



Digest Continued

hospital's Internet web site and sets forth requirements. Requires: (1) a provider facility (including a hospital) in which a nonemergency health care service will be performed; or (2) a practitioner (including a physician) who will perform a nonemergency health care service; upon request from the individual for whom the nonemergency health care service has been ordered, scheduled, or referred, to provide a good faith estimate of the price for the nonemergency health care service not more than three business days after receiving the individual's request. Requires a provider facility or practitioner to include the address of the service facility location to obtain reimbursement for a commercial claim for health care services. Requires a health carrier (including an insurer or a health maintenance organization) to provide to an individual who is entitled to coverage from the health carrier, not more than three business days after the individual requests the information, a good faith estimate of: (1) the amount of the cost of the nonemergency health care service that the health carrier will pay for or reimburse to the covered individual; or (2) the extent and nature of the ordered nonemergency health care service a covered individual is entitled to receive. Requires the department of insurance to submit a request for information and a request for proposal concerning the establishment and implementation of an all payer claims data base and sets forth requirements. Provides that if a health carrier provides coverage to the individual through a network plan, the health carrier shall inform the individual whether the provider facility in which the nonemergency health care service will be provided and the practitioners who will provide the nonemergency health care service are included in the health carrier's network plan. Requires provider facilities to post signs in waiting rooms and to provide Internet web site notices about the availability of estimates of the amount the patient will be charged for medical services. Requires practitioners to provide notice about the availability of estimates of the amount the patient will be charged for medical services when the practitioner has ordered, scheduled, or referred the individual for a nonemergency health care service. Requires health carriers to provide Internet web site notices about the availability of good faith estimates of coverage for nonemergency health care services. Provides penalties for noncompliance by provider facilities, practitioners, and health carriers. Requires an insurance producer to disclose commission information. Prohibits health provider contracts and contracts between a provider and a pharmacy benefits manager from including provisions that prohibit the disclosure of health care service claims data to employers providing the health coverage and makes a violation an unfair and deceptive act. Provides that a fully credentialed provider shall be reimbursed by an insurer or health maintenance organization for eligible services provided at an in-network hospital if certain conditions are met.



Second Regular Session of the 121st General Assembly (2020)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in this style type.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or *this style type* reconciles conflicts between statutes enacted by the 2019 Regular Session of the General Assembly.

HOUSE BILL No. 1005

A BILL FOR AN ACT to amend the Indiana Code concerning health.

Be it enacted by the General Assembly of the State of Indiana:

1	SECTION 1. IC 5-14-3-2, AS AMENDED BY P.L.85-2017,
2	SECTION 12, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
3	JULY 1, 2020]: Sec. 2. (a) The definitions set forth in this section apply
4	throughout this chapter.
5	(b) "Copy" includes transcribing by handwriting, photocopying,
6	xerography, duplicating machine, duplicating electronically stored data
7	onto a disk, tape, drum, or any other medium of electronic data storage,
8	and reproducing by any other means.
9	(c) "Criminal intelligence information" means data that has been
10	evaluated to determine that the data is relevant to:
11	(1) the identification of; and
12	(2) the criminal activity engaged in by;
13	an individual who or organization that is reasonably suspected of
14	involvement in criminal activity.
15	(d) "Direct cost" means one hundred five percent (105%) of the sum



1	of the cost of:
2	(1) the initial development of a program, if any;
3	(2) the labor required to retrieve electronically stored data; and
4	(3) any medium used for electronic output;
5	for providing a duplicate of electronically stored data onto a disk, tape,
6	drum, or other medium of electronic data retrieval under section 8(g)
7	of this chapter, or for reprogramming a computer system under section
8	6(c) of this chapter.
9	(e) "Electronic map" means copyrighted data provided by a public
0	agency from an electronic geographic information system.
1	(f) "Enhanced access" means the inspection of a public record by a
2	person other than a governmental entity and that:
3	(1) is by means of an electronic device other than an electronic
4	device provided by a public agency in the office of the public
5	agency; or
6	(2) requires the compilation or creation of a list or report that does
7	not result in the permanent electronic storage of the information.
8	(g) "Facsimile machine" means a machine that electronically
9	transmits exact images through connection with a telephone network
0.0	(h) "Inspect" includes the right to do the following:
1	(1) Manually transcribe and make notes, abstracts, or memoranda.
22	(2) In the case of tape recordings or other aural public records, to
23	listen and manually transcribe or duplicate, or make notes,
23 24 25 26	abstracts, or other memoranda from them.
2.5	(3) In the case of public records available:
26	(A) by enhanced access under section 3.5 of this chapter; or
27	(B) to a governmental entity under section 3(c)(2) of this
28	chapter;
.9	to examine and copy the public records by use of an electronic
0	device.
1	(4) In the case of electronically stored data, to manually transcribe
2	and make notes, abstracts, or memoranda or to duplicate the data
3	onto a disk, tape, drum, or any other medium of electronic
4	storage.
5	(i) "Investigatory record" means information compiled in the course
6	of the investigation of a crime.
7	(j) "Law enforcement activity" means:
8	(1) a traffic stop;
9	(2) a pedestrian stop;
-0	(3) an arrest;
-1	(4) a search;
.2	(5) an investigation:



1	(6) a pursuit;
2	(7) crowd control;
3	(8) traffic control; or
4	(9) any other instance in which a law enforcement officer is
5	enforcing the law.
6	The term does not include an administrative activity, including the
7	completion of paperwork related to a law enforcement activity, or a
8	custodial interrogation conducted in a place of detention as described
9	in Indiana Evidence Rule 617, regardless of the ultimate admissibility
10	of a statement made during the custodial interrogation.
11	(k) "Law enforcement recording" means an audio, visual, or
12	audiovisual recording of a law enforcement activity captured by a
13	camera or other device that is:
14	(1) provided to or used by a law enforcement officer in the scope
15	of the officer's duties; and
16	(2) designed to be worn by a law enforcement officer or attached
17	to the vehicle or transportation of a law enforcement officer.
18	(l) "Offender" means a person confined in a penal institution as the
19	result of the conviction for a crime.
20	(m) "Patient" has the meaning set out in IC 16-18-2-272(d).
21	(n) "Person" means an individual, a corporation, a limited liability
22	company, a partnership, an unincorporated association, or a
23	governmental entity.
24	(o) "Private university police department" means the police officers
25	appointed by the governing board of a private university under
26	IC 21-17-5.
27	(p) "Provider" has the meaning set out in IC 16-18-2-295(b)
28	IC 16-18-2-295(c) and includes employees of the state department of
29	health or local boards of health who create patient records at the
30	request of another provider or who are social workers and create
31	records concerning the family background of children who may need
32	assistance.
33	(q) "Public agency", except as provided in section 2.1 of this
34	chapter, means the following:
35	(1) Any board, commission, department, division, bureau,
36	committee, agency, office, instrumentality, or authority, by
37	whatever name designated, exercising any part of the executive,
38	administrative, judicial, or legislative power of the state.
39	(2) Any:
40	(A) county, township, school corporation, city, or town, or any
41	board, commission, department, division, bureau, committee,
42	office, instrumentality, or authority of any county, township,



1	school corporation, city, or town;
2	(B) political subdivision (as defined by IC 36-1-2-13); or
3	(C) other entity, or any office thereof, by whatever name
4	designated, exercising in a limited geographical area the
5	executive, administrative, judicial, or legislative power of the
6	state or a delegated local governmental power.
7	(3) Any entity or office that is subject to:
8	(A) budget review by either the department of local
9	government finance or the governing body of a county, city,
10	town, township, or school corporation; or
11	(B) an audit by the state board of accounts that is required by
12	statute, rule, or regulation.
13	(4) Any building corporation of a political subdivision that issues
14	bonds for the purpose of constructing public facilities.
15	(5) Any advisory commission, committee, or body created by
16	statute, ordinance, or executive order to advise the governing
17	body of a public agency, except medical staffs or the committees
18	of any such staff.
19	(6) Any law enforcement agency, which means an agency or a
20	department of any level of government that engages in the
21	investigation, apprehension, arrest, or prosecution of alleged
22	criminal offenders, such as the state police department, the police
23	
24	or sheriff's department of a political subdivision, prosecuting
	attorneys, members of the excise police division of the alcohol
25	and tobacco commission, conservation officers of the department
26	of natural resources, gaming agents of the Indiana gaming
27	commission, gaming control officers of the Indiana gaming
28	commission, and the security division of the state lottery
29	commission.
30	(7) Any license branch operated under IC 9-14.1.
31	(8) The state lottery commission established by IC 4-30-3-1,
32	including any department, division, or office of the commission.
33	(9) The Indiana gaming commission established under IC 4-33,
34	including any department, division, or office of the commission.
35	(10) The Indiana horse racing commission established by IC 4-31,
36	including any department, division, or office of the commission.
37	(11) A private university police department. The term does not
38	include the governing board of a private university or any other
39	department, division, board, entity, or office of a private
40	university.
41	(r) "Public record" means any writing, paper, report, study, map,

photograph, book, card, tape recording, or other material that is



created, received, retained, maintained, or filed by or with a public
agency and which is generated on paper, paper substitutes,
photographic media, chemically based media, magnetic or machine
readable media, electronically stored data, or any other material,
regardless of form or characteristics.

- (s) "Standard-sized documents" includes all documents that can be mechanically reproduced (without mechanical reduction) on paper sized eight and one-half (8 1/2) inches by eleven (11) inches or eight and one-half (8 1/2) inches by fourteen (14) inches.
 - (t) "Trade secret" has the meaning set forth in IC 24-2-3-2.
- (u) "Work product of an attorney" means information compiled by an attorney in reasonable anticipation of litigation. The term includes the attorney's:
 - (1) notes and statements taken during interviews of prospective witnesses; and
 - (2) legal research or records, correspondence, reports, or memoranda to the extent that each contains the attorney's opinions, theories, or conclusions.

This definition does not restrict the application of any exception under section 4 of this chapter.

SECTION 2. IC 12-26-2-5, AS AMENDED BY P.L.1-2007, SECTION 126, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]: Sec. 5. (a) This section applies under the following statutes:

- (1) IC 12-26-6.
- (2) IC 12-26-7.
- (3) IC 12-26-12.
- 28 (4) IC 12-26-15.
 - (b) A petitioner may be represented by counsel.
 - (c) The court may appoint counsel for a petitioner upon a showing of the petitioner's indigency and the court shall pay for such counsel if appointed.
 - (d) A petitioner, including a petitioner who is a health care provider under IC 16-18-2-295(b), IC 16-18-2-295(c), in the petitioner's individual capacity or as a corporation is not required to be represented by counsel. If a petitioner who is a corporation elects not to be represented by counsel, the individual representing the corporation at the commitment hearing must present the court with written authorization from:
 - (1) an officer;
 - (2) a director;
- 42 (3) a principal; or



1	(4) a manager;
2	of the corporation that authorizes the individual to represent the interest
3	of the corporation in the proceedings.
4	(e) The petitioner is required to prove by clear and convincing
5	evidence that:
6	(1) the individual is mentally ill and either dangerous or gravely
7	disabled; and
8	(2) detention or commitment of that individual is appropriate.
9	SECTION 3. IC 16-18-2-46.5 IS ADDED TO THE INDIANA
10	CODE AS A NEW SECTION TO READ AS FOLLOWS
11	[EFFECTIVE JULY 1, 2020]: Sec. 46.5. "Canadian supplier", for
12	purposes of IC 16-47-3, has the meaning set forth in IC 16-47-3-1.
13	SECTION 4. IC 16-18-2-88.3 IS ADDED TO THE INDIANA
14	CODE AS A NEW SECTION TO READ AS FOLLOWS
15	[EFFECTIVE JULY 1, 2020]: Sec. 88.3. "Covered individual", for
16	purposes of IC 16-21-15, has the meaning set forth in
17	IC 16-21-15-1.
18	SECTION 5. IC 16-18-2-148.7 IS ADDED TO THE INDIANA
19	CODE AS A NEW SECTION TO READ AS FOLLOWS
20	[EFFECTIVE JULY 1, 2020]: Sec. 148.7. "Good faith estimate", for
21	purposes of IC 16-21-15, has the meaning set forth in
22	IC 16-21-15-2.
23	SECTION 6. IC 16-18-2-163.6 IS ADDED TO THE INDIANA
24	CODE AS A NEW SECTION TO READ AS FOLLOWS
25	[EFFECTIVE JULY 1, 2020]: Sec. 163.6. "Health care services", for
26	purposes of IC 16-51-1, has the meaning set forth in IC 16-51-1-1.
27	SECTION 7. IC 16-18-2-163.8 IS ADDED TO THE INDIANA
28	CODE AS A NEW SECTION TO READ AS FOLLOWS
29	[EFFECTIVE JULY 1, 2020]: Sec. 163.8. "Health carrier", for
30	purposes of IC 16-21-15, has the meaning set forth in
31	IC 16-21-15-3.
32	SECTION 8. IC 16-18-2-190.5 IS ADDED TO THE INDIANA
33	CODE AS A NEW SECTION TO READ AS FOLLOWS
34	[EFFECTIVE JULY 1, 2020]: Sec. 190.5. "In network", for purposes
35	of IC 16-21-15, has the meaning set forth in IC 16-21-15-4.
36	SECTION 9. IC 16-18-2-216 IS AMENDED TO READ AS
37	FOLLOWS [EFFECTIVE JULY 1, 2020]: Sec. 216. (a)
38	"Manufacturer", for purposes of IC 16-42-19 and IC 16-42-21, means
39	a person who by compounding, cultivating, harvesting, mixing, or other
40	process produces or prepares legend drugs. The term includes a person
41	who:

(1) prepares legend drugs in dosage forms by mixing,



	I
1	compounding, encapsulating, entableting, or other process; or
2	(2) packages or repackages legend drugs.
3	(b) The term does not include pharmacists or practitioners (as
4	defined in section 288(a) 288(b) and 288(c) 288(d) of this chapter) in
5	the practice of their profession.
6	SECTION 10. IC 16-18-2-247.5 IS ADDED TO THE INDIANA
7	CODE AS A NEW SECTION TO READ AS FOLLOWS
8	[EFFECTIVE JULY 1, 2020]: Sec. 247.5. "Network", for purposes
9	of IC 16-21-15, has the meaning set forth in IC 16-21-15-5.
10	SECTION 11. IC 16-18-2-247.6 IS ADDED TO THE INDIANA
11	CODE AS A NEW SECTION TO READ AS FOLLOWS
12	[EFFECTIVE JULY 1, 2020]: Sec. 247.6. "Network plan", for
13	purposes of IC 16-21-15, has the meaning set forth in
14	IC 16-21-15-6.
15	SECTION 12. IC 16-18-2-250.5 IS ADDED TO THE INDIANA
16	CODE AS A NEW SECTION TO READ AS FOLLOWS
17	[EFFECTIVE JULY 1, 2020]: Sec. 250.5. "Nonemergency health
18	care service", for purposes of IC 16-21-15, has the meaning set
19	forth in IC 16-21-15-7.
20	SECTION 13. IC 16-18-2-254.4 IS ADDED TO THE INDIANA
21	CODE AS A NEW SECTION TO READ AS FOLLOWS
22	[EFFECTIVE JULY 1, 2020]: Sec. 254.4. "Off-campus location of a
23	hospital", for purposes of IC 16-21-16, has the meaning set forth
24	in IC 16-21-16-3.
25	SECTION 14. IC 16-18-2-288, AS AMENDED BY P.L.96-2014,
26	SECTION 4, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
27	JULY 1, 2020]: Sec. 288. (a) "Practitioner", for purposes of
28	IC 16-21-15, has the meaning set forth in IC 16-21-15-8.
29	(a) (b) "Practitioner", for purposes of IC 16-42-19, has the meaning
30	set forth in IC 16-42-19-5.
31	(b) (c) "Practitioner", for purposes of IC 16-41-14, has the meaning
32	set forth in IC 16-41-14-4.
33	(c) (d) "Practitioner", for purposes of IC 16-42-21, has the meaning
34	set forth in IC 16-42-21-3.
35	(d) (e) "Practitioner", for purposes of IC 16-42-22 and IC 16-42-25,
36	has the meaning set forth in IC 16-42-22-4.5.
37	(f) "Practitioner", for purposes of IC 16-51-1, has the meaning
38	set forth in IC 16-51-1-4.
39	SECTION 15. IC 16-18-2-294.5, AS AMENDED BY P.L.208-2015,
40	SECTION 4, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
41	JULY 1, 2020]: Sec. 294.5. (a) "Program", for purposes of IC 16-40-4,
42	has the meaning set forth in IC 16-40-4-3.



l	(b) "Program", for purposes of IC 16-41-7.5, has the meaning set
2	forth in IC 16-41-7.5-2.
3	(c) "Program", for purposes of IC 16-47-1, has the meaning set forth
4	in IC 16-47-1-3.
5	(d) "Program", for purposes of IC 16-47-3, has the meaning set
6	forth in IC 16-47-3-2.
7	SECTION 16. IC 16-18-2-295, AS AMENDED BY P.L.161-2014,
8	SECTION 4, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
9	JULY 1, 2020]: Sec. 295. (a) "Provider", for purposes of IC 16-21-8,
10	has the meaning set forth in IC 16-21-8-0.2.
11	(b) "Provider", for purposes of IC 16-21-15, has the meaning set
12	forth in IC 16-21-15-9.
13	(b) (c) "Provider", for purposes of IC 16-38-5, IC 16-39 (except for
14	IC 16-39-7), and IC 16-41-1 through IC 16-41-9, means any of the
15	following:
16	(1) An individual (other than an individual who is an employee or
17	a contractor of a hospital, a facility, or an agency described in
18	subdivision (2) or (3)) who is licensed, registered, or certified as
19	a health care professional, including the following:
20	(A) A physician.
21	(B) A psychotherapist.
22	(C) A dentist.
23	(D) A registered nurse.
24	(E) A licensed practical nurse.
25	(F) An optometrist.
26	(G) A podiatrist.
27	(H) A chiropractor.
28	(I) A physical therapist.
29	(J) A psychologist.
30	(K) An audiologist.
31	(L) A speech-language pathologist.
32	(M) A dietitian.
33	(N) An occupational therapist.
34	(O) A respiratory therapist.
35	(P) A pharmacist.
36	(Q) A sexual assault nurse examiner.
37	(2) A hospital or facility licensed under IC 16-21-2 or IC 12-25 or
38	described in IC 12-24-1 or IC 12-29.
39	(3) A health facility licensed under IC 16-28-2.
40	(4) A home health agency licensed under IC 16-27-1.
41	(5) An employer of a certified emergency medical technician, a
12	certified advanced emergency medical technician, or a licensed



1	paramedic.
2	(6) The state department or a local health department or an
3	employee, agent, designee, or contractor of the state department
4	or local health department.
5	(c) (d) "Provider", for purposes of IC 16-39-7-1, has the meaning set
6	forth in IC 16-39-7-1(a).
7	(d) (e) "Provider", for purposes of IC 16-48-1, has the meaning set
8	forth in IC 16-48-1-3.
9	SECTION 17. IC 16-18-2-295.5 IS ADDED TO THE INDIANA
10	CODE AS A NEW SECTION TO READ AS FOLLOWS
11	[EFFECTIVE JULY 1, 2020]: Sec. 295.5. "Provider facility", for
12	purposes of IC 16-21-15, has the meaning set forth in
13	IC 16-21-15-10.
14	SECTION 18. IC 16-18-2-328.7 IS ADDED TO THE INDIANA
15	CODE AS A NEW SECTION TO READ AS FOLLOWS
16	[EFFECTIVE JULY 1, 2020]: Sec. 328.7. "Service facility location",
17	for purposes of IC 16-51-1, has the meaning set forth in
18	IC 16-51-1-6.
19	SECTION 19. IC 16-18-2-353.3 IS ADDED TO THE INDIANA
20	CODE AS A NEW SECTION TO READ AS FOLLOWS
21	[EFFECTIVE JULY 1, 2020]: Sec. 353.3. "Track-and-trace", for
22	purposes of IC 16-47-3, has the meaning set forth in IC 16-47-3-3.
23	SECTION 20. IC 16-18-2-362.1 IS ADDED TO THE INDIANA
24	CODE AS A NEW SECTION TO READ AS FOLLOWS
25	[EFFECTIVE JULY 1, 2020]: Sec. 362.1. "Urgent care facility", for
26	purposes of IC 16-24.5-1, has the meaning set forth in
27	IC 16-24.5-1-1.
28	SECTION 21. IC 16-18-2-363.5 IS ADDED TO THE INDIANA
29	CODE AS A NEW SECTION TO READ AS FOLLOWS
30	[EFFECTIVE JULY 1, 2020]: Sec. 363.5. "Vendor", for purposes of
31	IC 16-47-3, has the meaning set forth in IC 16-47-3-4.
32	SECTION 22. IC 16-21-3-2, AS AMENDED BY P.L.197-2011,
33	SECTION 61, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
34	JULY 1, 2020]: Sec. 2. (a) The state health commissioner may take
35	action under section 1 of this chapter on any of the following grounds:
36	(1) Violation of any of the provisions of this chapter or of the
37	rules adopted under this chapter.
38	(2) Permitting, aiding, or abetting the commission of any illegal
39	act in an institution.
40	(3) Knowingly collecting or attempting to collect from a
41	subscriber (as defined in IC 27-13-1-32) or an enrollee (as defined

in IC 27-13-1-12) of a health maintenance organization (as



1	defined in IC 27-13-1-19) any amounts that are owed by the
2	health maintenance organization.
3	(4) Conduct or practice found by the state department to be
4	detrimental to the welfare of the patients of an institution.
5	(b) The state health commissioner may take action:
6	(1) under section 1(1) or 1(2) of this chapter for an initial
7	violation or isolated violations of IC 16-21-15; or
8	(2) under section 1(4) or 1(5) of this chapter for repeated or
9	persistent violations of IC 16-21-15;
10	concerning the providing of a good faith estimate within three (3)
11	business days to an individual for whom a nonemergency health
12	care service has been ordered.
13	SECTION 23. IC 16-21-15 IS ADDED TO THE INDIANA CODE
14	AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE
15	JULY 1, 2020]:
16	Chapter 15. Provider Facility Good Faith Estimates
17	Sec. 0.5. Nothing in this chapter prohibits:
18	(1) a self-funded health benefit plan that complies with the
19	federal Employee Retirement Income Security Act (ERISA)
20	of 1974 (29 U.S.C. 1001 et seq.); or
21	(2) a self-insurance program established to provide group
22	health coverage as described in IC 5-10-8-7(b), or a contract
23	for health services as described in IC 5-10-8-7(c);
24	from providing information requested by a practitioner or
25	provider facility under this chapter.
26	Sec. 1. As used in this chapter, "covered individual" means an
27	individual who is entitled to be provided health care services
28	according to a health carrier's network plan.
29	Sec. 2. As used in this chapter, "good faith estimate" means a
30	reasonable estimate of the total price a provider anticipates
31	charging for one (1) or more nonemergency health care services
32	that:
33	(1) is made by a provider under this chapter upon the request
34	of the individual for whom the nonemergency health care
35	service has been ordered; and
36	(2) is not binding upon the provider.
37	Sec. 3. (a) As used in this chapter, "health carrier" means an
38	entity:
39	(1) that is subject to IC 27 and the administrative rules
40	adopted under IC 27; and
41	(2) that enters into a contract to:
42	(A) provide health care services;



1	(B) deliver health care services;
2	(C) arrange for health care services; or
3	(D) pay for or reimburse any of the costs of health care
4	services.
5	(b) The term includes the following:
6	(1) An insurer, as defined in IC 27-1-2-3(x), that issues a
7	policy of accident and sickness insurance, as defined in
8	IC 27-8-5-1(a).
9	(2) A health maintenance organization, as defined in
10	IC 27-13-1-19.
11	(3) An administrator (as defined in IC 27-1-25-1(a)) that is
12	licensed under IC 27-1-25.
13	(4) Any other entity that provides a plan of health insurance,
14	health benefits, or health care services.
15	Sec. 4. As used in this chapter, "in network", when used in
16	reference to a provider, means that the health care services
17	provided by the provider are subject to a health carrier's network
18	plan.
19	Sec. 5. (a) As used in this chapter, "network" means a group of
20	provider facilities and practitioners that:
21	(1) provide health care services to covered individuals; and
22 23	(2) have agreed to, or are otherwise subject to, maximum
23	limits on the fees and charges for the health care services to be
24	provided to the covered individuals.
25	(b) The term includes the following:
26	(1) A network described in subsection (a) that is established
27	pursuant to a contract between an insurer providing coverage
28	under a group health policy and:
29	(A) individual provider facilities and practitioners;
30	(B) a preferred provider organization; or
31	(C) an entity that employs or represents providers,
32	including:
33	(i) an independent practice association; and
34	(ii) a physician-hospital organization.
35	(2) A health management organization, as defined in
36	IC 27-13-1-19.
37	Sec. 6. As used in this chapter, "network plan" means a plan of
38	a health carrier that:
39	(1) requires a covered person to receive; or
40	(2) creates incentives, including financial incentives, for a
41	covered person to receive;
42	health care services from one (1) or more providers that are under



1	contract with, managed by, or owned by the health carrier.
2	Sec. 7. (a) As used in this chapter, "nonemergency health care
3	service" means a service or series of services ordered, scheduled,
4	or referred by a practitioner for the purpose of:
5	(1) diagnosis;
6	(2) prevention;
7	(3) treatment;
8	(4) cure; or
9	(5) relief;
10	of a physical, mental, or behavioral health condition, illness, injury,
11	or disease that is not provided on an emergency basis.
12	Sec. 8. As used in this chapter, "practitioner" means:
13	(1) an individual who holds a license, certificate, registration,
14	or permit under:
15	(A) IC 25-22.5 (physicians);
16	(B) IC 25-27 (physical therapists); or
17	(C) IC 25-33 (psychologists); or
18	(2) an organization consisting of or employing two (2) or more
19	individuals described in subdivision (1).
20	Sec. 8.5. As used in this chapter, "price" means the negotiated
21	rate between the:
22	(1) provider facility and practitioner; and
23 24	(2) covered individual's health carrier.
24	Sec. 9. As used in this chapter, "provider" means:
25	(1) a provider facility; or
26	(2) a practitioner.
27	Sec. 10. As used in this chapter, "provider facility" means any of
28	the following:
29	(1) A hospital licensed under IC 16-21-2.
30	(2) An ambulatory outpatient surgery center licensed under
31	IC 16-21-2.
32	(3) An abortion clinic licensed under IC 16-21-2.
33	(4) A birthing center licensed under IC 16-21-2.
34	(5) A facility that provides diagnostic services to the medical
35	profession or the general public, including outpatient
36	facilities.
37	(6) A laboratory where clinical pathology tests are carried out
38	on specimens to obtain information about the health of a
39	patient.
40	(7) A facility where radiologic and electromagnetic images are
41	made to obtain information about the health of a patient.
12	(8) An infusion center that administers intravenous



1	medications.
2	Sec. 11. (a) This section does not:
3	
4	(1) apply to a individual who is a Medicaid recipient; or
5	(2) limit the authority of a legal representative of the patient.
	(b) An individual for whom a nonemergency health care service
6	has been ordered may request from the provider facility in which
7	the health care service will be provided a good faith estimate of the
8	total price that will be charged as a result of the nonemergency
9	health care service.
10	(c) A provider facility that receives a request from an individual
11	under subsection (b) shall, not more than three (3) business days
12	after receiving the request, provide to the individual a good faith
13	estimate of:
14	(1) the total price that the provider facility in which the health
15	care service will be performed will impose for:
16	(A) the use of the provider facility to care for the
17	individual before, during, and after the nonemergency
18	health care service;
19	(B) the services rendered by the staff of the provider
20	facility in connection with the nonemergency health care
21	service; and
22	(C) medication, supplies, equipment, and material items to
23	be provided to or used by the individual while the
24	individual is present in the provider facility in connection
25	with the nonemergency health care service; and
26	(2) fees charged for the services of all practitioners, support
27	staff, and other persons who provide professional health
28	services:
29	(A) who will provide services to or for the individual
30	during the individual's presence in the provider facility for
31	the nonemergency health care service; and
32	(B) for whose services the individual will be charged
33	separately from the charge of the provider facility.
34	(d) The charges that must be included in a good faith estimate
35	under this section include all charges under subsection (c)(1) or
36	(c)(2) for imaging, laboratory services, diagnostic services, therapy,
37	observation services, and other services expected to be provided to
38	the individual.
39	(e) A provider facility must ensure that a good faith estimate
40	provided to an individual under this section is accompanied by a
41	notice stating that:

(1) an estimate provided under this section is not binding on



1	the provider facility; and
2	(2) the price the provider facility charges the individual may
3	vary from the estimate based on the individual's medical
4	needs.
5	(f) A provider facility may not charge a patient for information
6	provided under this section.
7	Sec. 12. (a) If:
8	(1) the individual who requests a good faith estimate from a
9	provider facility under this chapter and has been verified as
10	a covered individual with respect to a network plan; and
11	(2) the provider facility from which the individual requests
12	the good faith estimate is in network with respect to the same
13	network plan;
14	the good faith estimate that the provider facility provides to the
15	individual under this chapter must be based on the negotiated
16	charges to which the provider facility and any practitioners
17	referred to in section 11(c)(2) of this chapter have agreed as in
18	network providers.
19	(b) If the individual who requests a good faith estimate from a
20	provider facility under this chapter:
21	(1) is not a covered individual with respect to any network
22	plan; or
23	(2) is not a covered individual with respect to a network plan
24	with respect to which the provider facility is in network;
25	the good faith estimate that the provider facility provides to the
26	individual under this chapter must be based on the amounts that
27	the provider facility and any practitioners referred to in section
28	11(c)(2) of this chapter charge for the nonemergency health care
29	services in the absence of any network plan.
30	Sec. 13. A provider facility may provide a good faith estimate to
31	an individual under this chapter:
32	(1) in a writing delivered to the individual;
33	(2) by electronic mail; or
34	(3) through a mobile application;
35	according to the preference expressed by the individual.
36	Sec. 14. (a) A good faith estimate provided by a provider facility
37	to an individual under this chapter must:
38	(1) state the services and material items that the good faith
39	estimate is based on;
40	(2) set forth the estimated price for the services and material
41	items referred to in subdivision (1); and
42	(3) include a total figure that is a sum of the estimated prices



1	referred to in subdivision (2).
2	(b) Subsection (a) does not prohibit a provider facility from
3	providing to an individual a good faith estimate that indicates how
4	much of the total figure stated under subsection (a)(3) will be the
5	individual's out-of-pocket expense after the health carrier's
6	payment of charges.
7	(c) A health carrier must provide a provider facility with timely
8	information needed by the provider facility to comply with the
9	requirements under this chapter.
10	Sec. 15. (a) As used in this section, "waiting room" means a
11	space in a building used by a provider facility in which people
12	check in or register to:
13	(1) be seen by practitioners; or
14	(2) meet with members of the staff of the provider facility.
15	(b) A provider facility shall ensure that each waiting room of the
16	provider facility includes at least one (1) printed notice that:
17	(1) is designed, lettered, and positioned within the waiting
18	room so as to be conspicuous to and readable by any
19	individual with normal vision who visits the waiting room;
20	and
21	(2) states the following, or words to the same effect: "A
22	patient may ask for an estimate of the amount the patient will
23	be charged for a nonemergency medical service provided in
24	this facility. The law requires that an estimate be provided
25	within 3 business days.".
26	(c) If a provider facility maintains an Internet web site, the
27	provider facility shall ensure that the Internet web site includes at
28	least one (1) printed notice that:
29	(1) is designed, lettered, and featured on the Internet web site
30	so as to be conspicuous to and readable by any individual with
31	normal vision who visits the Internet web site; and
32	(2) states the following, or words to the same effect: "A
33	patient may ask for an estimate of the amount the patient will
34	be charged for a nonemergency medical service provided in
35	our facility. The law requires that an estimate be provided
36	within 3 business days.".
37	SECTION 24. IC 16-21-17 IS ADDED TO THE INDIANA CODE
38	AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE
39	JULY 1, 2020]:
40	Chapter 17. Health Care Pricing Information

Sec. 1. (a) Not later than March 31, 2021, a hospital and an ambulatory surgical center shall post on the Internet web site of



41

1	the hospital or ambulatory outpatient surgical center pricing and
2	other information specified in this chapter for the following:
3	(1) For as many of the seventy (70) shoppable services
4	specified in 45 CFR 180 (as published August 9, 2019, and as
5	subsequently amended) that are provided by the hospital or
6	ambulatory outpatient surgical center.
7	(2) In addition to the services specified in subdivision (1), the
8	thirty (30) most common services that are provided by the
9	hospital or ambulatory outpatient surgical center.
10	(b) The following information must be included on the Internet
11	web site by a hospital and an ambulatory outpatient surgical center
12	for each billing code, including, if relevant, each diagnosis related
13	group (DRG) billing code and each health care common procedure
14	coding system (HCPCS) billing code:
15	(1) The number of services provided for the code.
16	(2) A description of the service.
17	(3) The weighted average prices paid per service per provider
18	type for each of the following categories:
19	(A) Employer sponsored insurance.
20	(B) Individually purchased insurance.
21	(C) Medicare, including fee for service and Medicare
22	Advantage.
23	(D) Self pay without charitable assistance from the hospital
24	or ambulatory surgical center.
25	(E) Self pay with charitable assistance from the hospital or
26	ambulatory surgical center.
27	Sec. 2. (a) The information displayed on the Internet web site
28	must be in an easy to read, understandable format, and include the
29	prices for each billing code by provider type.
30	(b) A hospital and an ambulatory outpatient surgical center
31	shall update the information on the Internet web site on a
32	quarterly basis.
33	SECTION 25. IC 16-24.5 IS ADDED TO THE INDIANA CODE
34	AS A NEW ARTICLE TO READ AS FOLLOWS [EFFECTIVE JULY
35	1, 2020]:
36	ARTICLE 24.5. OTHER HEALTH CARE FACILITIES
37	Chapter 1. Urgent Care Facilities
38	Sec. 1. (a) As used in this chapter, "urgent care facility" means
39	a free standing health care facility that offers episodic, walk-in care
40	for the treatment of acute, but not life-threatening, health
41	conditions.
42	(b) The term does not include an emergency department of a



1	hospital or a nonprofit or government operated health clinic.
2	Sec. 2. (a) Not later than March 31, 2021, an urgent care facility
3	shall post on the Internet web site of the urgent care facility pricing
4	and other information specified in this chapter for the fifteen (15)
5	most common services that are provided by the urgent care
6	facility.
7	(b) The following information must be included on the Internet
8	web site by an urgent care facility for each billing code, including,
9	if relevant, each diagnosis related group (DRG) billing code and
10	each health care common procedure coding system (HCPCS)
11	billing code:
12	(1) The number of services provided for the code.
13	(2) A description of the service.
14	(3) The weighted average prices paid per service per provider
15	type for each of the following categories:
16	(A) Employer sponsored insurance.
17	(B) Individually purchased insurance.
18	(C) Medicare, including fee for service and Medicare
19	Advantage.
20	(D) Self pay without charitable assistance from the hospital
21	or ambulatory surgical center.
22	(E) Self pay with charitable assistance from the hospital or
23	ambulatory surgical center.
24	Sec. 3. (a) The information displayed on the Internet web site
25	must be in an easy to read, understandable format, and include the
26	prices for each billing code by provider type.
27	(b) An urgent care facility shall update the information on the
28	Internet web site on a quarterly basis.
29	SECTION 26. IC 16-47-3 IS ADDED TO THE INDIANA CODE
30	AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE
31	JULY 1, 2020]:
32	Chapter 3. Importation of Prescription Drugs Program
33	Sec. 1. As used in this chapter, "Canadian supplier" means a:
34	(1) manufacturer;
35	(2) wholesale drug distributor; or
36	(3) pharmacy;
37	appropriately licensed or permitted under Canadian law to
38	manufacture, distribute, or dispense prescription drugs.
39	Sec. 2. As used in this chapter, "program" refers to the
40	importation of prescription drugs program established by section
41	5 of this chapter.
42	Sec. 3. As used in this chapter, "track-and-trace" means the



	18
1	product-tracing process for the components of the pharmaceutical
2	distribution supply chain, as described in Title II of the federal
3	Drug Quality and Security Act (21 U.S.C. 351 et seq.).
4	Sec. 4. As used in this chapter, "vendor" means an entity that
5	contracts with the state department to manage specified functions
6	of the program.
7	Sec. 5. (a) The importation of prescription drugs program is
8	established.
9	(b) The state department shall administer the program.
10	(c) The state department shall contract with a vendor to provide
11	services under the program. The vendor must comply with the
12	requirements of this chapter.
13	(d) The state department shall require a bond from the vendor
14	to mitigate the financial consequences of potential acts of
15	malfeasance or misfeasance, potential fraudulent acts, or potential
16	dishonest acts committed by the vendor, an employee of the
17	vendor, or a contractor or subcontractor of the vendor.
18	(e) Before July 1, 2021, the state department shall apply to the
19	United States Department of Health and Human Services for
20	approval of the program under 21 U.S.C. 384(1). The state
21	department shall implement the program not later than six (6)

(1) A description of the state department's plan for operating the program.

months after the state department receives approval for the

program. The request must include the following:

- (2) A demonstration of how the prescription drugs imported into Indiana under the program will meet the applicable federal and state standards for safety and effectiveness.
- (3) A demonstration of how the prescription drugs imported into Indiana under the program will comply with federal track-and-trace procedures.
- (4) A list of proposed prescription drugs that have the highest potential for cost savings to the state through importation at the time that the request is submitted.
- (5) An estimate of the total cost savings attributable to the program.
- (6) The costs of program implementation to the state.
- (7) A list of potential Canadian suppliers from which the state would import the prescription drugs and a demonstration that the suppliers are in full compliance with relevant Canadian federal and provincial laws and regulations, as well as all applicable federal and state laws and regulations.



1	(f) Upon receipt of federal approval of the program, the state
2	department shall notify the following:
3	(1) The speaker of the house of representatives.
4	(2) The president pro tempore of the senate.
5	(3) The members of the health and provider services
6	committee in the senate.
7	(4) The members of the public health committee in the house
8	of representatives.
9	(g) Before the start of the general assembly session following
10	receipt of the federal approval, the state department shall submi
11	to the individuals described in subsection (f) a proposal for the
12	implementation of funding of the program.
13	Sec. 6. (a) Before December 1, 2020, and by December 1 of each
14	subsequent year, the vendor shall develop a wholesale prescription
15	drug importation list identifying the prescription drugs that have
16	the highest potential for cost savings to the state.
17	(b) In developing the list, the vendor shall consider at least the
18	following in determining whether a prescription drug should be
19	included on the list:
20	(1) Prescription drugs that, if included on the list, would
21	provide the highest potential for cost savings in state
22 23	administered programs.
23	(2) Prescription drugs for which there is a shortage in Indiana
24	or the United States.
25	(3) Specialty prescription drugs.
26	(4) High volume prescription drugs.
27	(c) The state department shall review the wholesale prescription
28	drug importation list at least every three (3) months to ensure that
29	the list continues to meet the requirements of the program. The
30	state department may direct the vendor to revise the list as
31	necessary.
32	Sec. 7. (a) The vendor shall identify Canadian suppliers that:
33	(1) are in full compliance with:
34	(A) relevant Canadian federal and provincial laws and
35	regulations; and
36	(B) the federal Drug Quality and Security Act;
37	(2) have agreed to export prescription drugs identified on the
38	list described in section 6 of this chapter at prices that will
39	provide cost savings to the state; and
40	(3) have obtained an international export pharmacy permit
11	1 100506145

(b) The vendor must verify that the Canadian suppliers meet all $\,$



1	of the requirements of the program while meeting or exceeding the
2	federal and state track-and-trace laws and regulations.
3	(c) The vendor shall:
4	(1) contract with an eligible Canadian supplier; or
5	(2) facilitate contracts between eligible importers and
6	Canadian suppliers;
7	to import drugs under the program.
8	(d) The vendor shall maintain a list of all registered importers
9	that participate in the program.
10	(e) The vendor shall ensure compliance with Title II of the
11	federal Drug Quality and Security Act by all suppliers, importers,
12	distributors, and participants in the program.
13	Sec. 8. (a) The vendor shall provide to the state department the
14	following:
15	(1) An annual financial audit of the vendor's operations.
16	(2) Quarterly financial reports specific to the program,
17	including information on the performance of the vendor and
18	the vendor's subcontractors for the program.
19	(b) The state department shall determine the format and
20	contents of the reports described in this section.
21	Sec. 9. (a) A Canadian supplier is eligible to participate in the
22	program if the Canadian supplier meets the following
23	requirements:
24	(1) Is in full compliance with relevant Canadian federal and
25	provincial laws and regulations.
26	(2) Is identified by the vendor as eligible to participate in the
27	program.
28	(3) Submits an attestation that the supplier has a registered
29	agent in the United States, including the name and United
30	States business address of the registered agent.
31	(b) An importer that meets the requirements of this chapter
32	may import a prescription drug from an eligible Canadian supplier
33	if the following conditions are met:
34	(1) The prescription drug meets the United States Food and
35	Drug Administration's standards concerning safety,
36	effectiveness, misbranding, and adulteration.
37	(2) The importation of the drug would not violate federal
38	patent laws.
39	(3) The importation of the drug is expected to generate cost
40	savings to the state.
41	(4) The drug is not any of the following:
42	(A) A controlled substance.



1	(B) A biological product.
2	(C) An infused drug.
3	(D) An intravenously injected drug.
4	(E) A drug that is inhaled during surgery.
5	(F) A drug that is a parenteral drug, the importation of
6	which is determined by the United States Secretary of
7	Health and Human Services to pose a threat to the public
8	health.
9	Sec. 10. (a) The following entities may import prescription drugs
10	under the program from a Canadian supplier that meets the
11	requirements of this chapter:
12	(1) A pharmacist or wholesale drug distributor employed by
13	or under contract with the state department for distribution
14	to a county health department for dispensing to the patients
15	of the county health department.
16	(2) A pharmacist or wholesale drug distributor employed by
17	or under contract with a pharmacy that is a Medicaid
18	provider, for dispensing to the pharmacy's Medicaid
19	recipients.
20	(3) A pharmacist or wholesale drug distributor employed by
21	or under contract with the department of correction, for
22	dispensing to inmates in the custody of the department of
23	correction.
24	(b) A Canadian supplier that meets the requirements of this
25	chapter and an eligible importer described in subsection (a) that is
26	participating in the program:
27	(1) must comply with all track-and-trace requirements; and
28	(2) may not distribute, dispense, or sell prescription drugs
29	imported under this program outside Indiana.
30	Sec. 11. (a) The vendor shall ensure the safety and quality of
31	drugs imported under the program.
32	(b) The vendor shall do the following:
33	(1) For an initial imported shipment of a specific drug by an
34	importer, ensure that each batch of the drug in the shipment
35	is statistically sampled and tested for authenticity and
36	degradation in a manner consistent with federal law.
37	(2) For every subsequent imported shipment of that drug by
38	that importer, ensure that a statistically valid sample of the
39	shipment is tested for authenticity and degradation in a
10	manner consistent with federal law.
1 1	(3) Certify that the drug:
12	(A) is approved for marketing in the United States and is



not adulterated or misbranded; and

2	(B) meets all of the labeling requirements under 21 U.S.C.
3	352.
4	(4) Maintain qualified laboratory records, including complete
5	data derived from all tests necessary to ensure that the drug
6	is in compliance with the requirements of this section.
7	(5) Maintain documentation demonstrating that the testing
8	required by this section was conducted at a qualified
9	laboratory in accordance with federal and state laws and
10	regulations governing laboratory qualifications.
11	(c) All testing required by this section must be conducted in a
12	qualified laboratory that meets the standards under federal and
13	state laws and regulations governing laboratory qualifications for
14	drug testing.
15	(d) The vendor shall maintain information and documentation
16	submitted under this section for at least seven (7) years.
17	Sec. 12. An importer participating in the program must submit
18	all of the following information to the vendor concerning drugs
19	provided for the program:
20	(1) The name and quantity of the active ingredients of the
21	drug.
22	(2) A description of the dosage form of the drug.
21 22 23 24	(3) The date on which the drug is received.
	(4) The quantity of the drug that is received.
25	(5) The point of origin and destination of the drug.
26	(6) The price paid by the importer for the drug.
27	Sec. 13. (a) A Canadian supplier participating in the program
28	must submit the following information and documentation to the
29	vendor specifying all of the following concerning drugs provided
30	for the program:
31	(1) The original source of the drug, including:
32	(A) the name of the manufacturer of the drug;
33	(B) the date on which the drug was manufactured; and
34	(C) the location, including the country, state or province
35	and city, where the drug was manufactured.
36	(2) The date on which the drug is shipped.
37	(3) The quantity of the drug that is shipped.
38	(4) The quantity of each lot of the drug originally received and
39	the source of the lot.
40	(5) The lot or control number and the batch number assigned
41	to the drug by the manufacturer.
42	(b) The state department may require that the yendor collect



1	additional information from the Canadian supplier that is
2	necessary to ensure the protection of the public health.
3	Sec. 14. (a) The state department shall immediately suspend the
4	importation of a specific drug or the importation of drugs by a
5	specific importer if the state department discovers that any drug
6	or importer activity is in violation of this chapter or any federal or
7	state law or regulation.
8	(b) The state department may revoke the suspension under
9	subsection (a) of the importation of a specific drug or the
10	importation of drugs by a specific importer if the state department
11	determines that the public is adequately protected from counterfeit
12	or unsafe drugs being imported into Indiana.
13	Sec. 15. Before December 1 of each year, the state department
14	shall submit a report to the governor and the general assembly in
15	an electronic format under IC 5-14-6 on the operation of the
16	program during the previous fiscal year. The report must include
17	at least the following:
18	(1) A list of the prescription drugs that were imported under
19	the program.
20	(2) The number of participating persons.
21	(3) The number of prescriptions dispensed through the
22	program.
23	(4) The estimated cost savings to the state during the previous
24	fiscal year and to date that are attributable to the program.
25	(5) A description of the methodology used to determine which
26	drugs should be included on the wholesale prescription drug
27	importation list.
28	(6) Documentation on how the program ensures the following:
29	(A) Canadian suppliers participating in the program are of
30	high quality and high performance and in full compliance
31	with relevant:
32	(i) Canadian federal and provincial laws and
33	regulations; and
34	(ii) federal and state laws, regulations, and rules.
35	(B) Prescription drugs imported under the program are
36	not shipped, sold, or dispensed outside Indiana once in the
37	possession of the importer.
38	(C) Prescription drugs imported under the program are
39	pure, unadulterated, potent, and safe.
40	(D) The program does not place consumers at a higher
41	health and safety risk than if the consumers did not
42	participate.



1	(E) The program provides cost savings to the state on
2	imported prescription drugs.
3	Sec. 16. The state department shall adopt rules under IC 4-22-2
4	necessary to implement this chapter.
5	SECTION 27. IC 16-51 IS ADDED TO THE INDIANA CODE AS
6	A NEW ARTICLE TO READ AS FOLLOWS [EFFECTIVE JULY 1,
7	2020]:
8	ARTICLE 51. HEALTH CARE REQUIREMENTS
9	Chapter 1. Health Care Billing
10	Sec. 1. (a) As used in this chapter, "health care services" means
11	health care related services or products rendered or sold by a
12	provider within the scope of the provider's license or legal
13	authorization.
14	(b) The term includes hospital, medical, surgical, dental, vision,
15	and pharmaceutical services or products.
16	Sec. 2. As used in this chapter, "health maintenance
17	organization" has the meaning set forth in IC 27-13-1-19.
18	Sec. 3. As used in this chapter, "insurer" has the meaning set
19	forth in IC 27-8-11-1(e).
20	Sec. 4. As used in this chapter, "practitioner" means an
21	individual or entity duly licensed or legally authorized to provide
22	health care services.
23	Sec. 5. As used in this chapter, "provider facility" means any of
24	the following:
25	(1) A hospital.
26	(2) A skilled nursing facility.
27	(3) An end stage renal disease provider.
28	(4) A home health agency.
29	(5) A hospice organization.
30	(6) An outpatient physical therapy, occupational therapy, or
31	speech pathology service provider.
32	(7) A comprehensive outpatient rehabilitation facility.
33	(8) A community mental health center.
34	(9) A critical access hospital.
35	(10) A federally qualified health center.
36	(11) A histocompatibility laboratory.
37	(12) An Indian health service facility.
38	(13) An organ procurement organization.
39	(14) A religious nonmedical health care institution.
40	(15) A rural health clinic.
41	Sec. 6. As used in this chapter, "service facility location" means
12	the address where the services of a provider facility or practitioner



1	were provided. The term consists of exact address and place of
2	service codes as required on CMS forms 1500 and 1450, including
3	an office, on-campus location of a hospital, and off-campus location
4	of a hospital.
5	Sec. 7. (a) A provider facility or practitioner shall include the
6	address of the service facility location in order to obtain
7	reimbursement for a commercial claim for health care services
8	from an insurer, health maintenance organization, employer, or
9	other person responsible for the payment of the cost of health care
10	services.
11	(b) An insurer, health maintenance organization, employer, or
12	other person responsible for the payment of the cost of health care
13	services is not required to accept a bill for health care services that
14	does not contain the service facility location.
15	Sec. 8. A patient is not liable for any additional payment that is
16	the result of a practitioner or provider facility filing an incorrect
17	form or not including the correct service facility location as
18	required under this chapter.
19	SECTION 28. IC 25-22.5-16 IS ADDED TO THE INDIANA
20	CODE AS A NEW CHAPTER TO READ AS FOLLOWS
21	[EFFECTIVE JULY 1, 2020]:
22	Chapter 16. Practitioner Good Faith Estimates
23	Sec. 1. As used in this chapter, "covered individual" means ar
24	individual who is entitled to be provided health care services
25	according to a health carrier's network plan.
26	Sec. 2. As used in this chapter, "good faith estimate" means a
27	reasonable estimate of the total price a practitioner anticipates
28	charging for one (1) or more nonemergency health care services
29	that:
30	(1) is made by a practitioner under this chapter upon the
31	request of:
32	(A) the individual for whom the nonemergency health care
33	service has been ordered; or
34	(B) the provider facility in which the nonemergency health
35	care service will be provided; and
36	(2) is not binding upon the practitioner.
37	Sec. 3. (a) As used in this chapter, "health carrier" means ar
38	entity:
39	(1) that is subject to IC 27 and the administrative rules
10	adopted under IC 27; and
11	(2) that enters into a contract to:
12	(A) provide health care services:



1	(B) deliver health care services;
2	(C) arrange for health care services; or
3	(D) pay for or reimburse any of the costs of health care
4	services.
5	(b) The term includes the following:
6	(1) An insurer, as defined in IC 27-1-2-3(x), that issues a
7	policy of accident and sickness insurance, as defined in
8	IC 27-8-5-1(a).
9	(2) A health maintenance organization, as defined in
0	IC 27-13-1-19.
1	(3) An administrator (as defined in IC 27-1-25-1(a)) that is
12	licensed under IC 27-1-25.
13	(4) Any other entity that provides a plan of health insurance,
14	health benefits, or health care services.
15	Sec. 4. As used in this chapter, "in network", when used in
16	reference to a practitioner, means that the health care services
17	provided by the practitioner are subject to a health carrier's
18	network plan.
19	Sec. 5. (a) As used in this chapter, "network" means a group of
20	provider facilities and practitioners that:
21	(1) provide health care services to covered individuals; and
22	(2) have agreed to, or are otherwise subject to, maximum
23	limits on the fees and charges for the health care services to be
24	provided to the covered individuals.
25	(b) The term includes the following:
26	(1) A network described in subsection (a) that is established
27	pursuant to a contract between an insurer providing coverage
28	under a group health policy and:
29	(A) individual provider facilities and practitioners;
30	(B) a preferred provider organization; or
31	(C) an entity that employs or represents providers,
32	including:
33	(i) an independent practice association; and
34	(ii) a physician-hospital organization.
35	(2) A health management organization, as defined in
36	IC 27-13-1-19.
37	Sec. 6. As used in this chapter, "network plan" means a plan of
38	a health carrier that:
39	(1) requires a covered person to receive; or
10	(2) creates incentives, including financial incentives, for a
11	covered person to receive;
12	health care services from one (1) or more providers that are under



1	contract with, managed by, or owned by the health carrier.
2	Sec. 7. (a) As used in this chapter, "nonemergency health care
3	service" means a service or series of services ordered, scheduled,
4	or referred by a practitioner for the:
5	(1) diagnosis;
6	(2) prevention;
7	(3) treatment;
8	(4) cure; or
9	(5) relief;
10	of a physical, mental, or behavioral health condition, illness, injury,
11	or disease that is not provided on an emergency basis.
12	Sec. 8. As used in this chapter, "practitioner" means:
13	(1) an individual who holds a license, certificate, registration,
14	or permit under:
15	(A) IC 25-22.5 (physicians);
16	(B) IC 25-27 (physical therapists); or
17	(C) IC 25-33 (psychologists); or
18	(2) an organization consisting of or employing two (2) or more
19	individuals described in subdivision (1).
20	Sec. 8.5. As used in this chapter, "price" means the negotiated
21	rate between the:
	(1) provider facility and practitioner; and
22 23	(2) covered individual's health carrier.
24	Sec. 9. As used in this chapter, "provider" means:
25	(1) a provider facility; or
26	(2) a practitioner.
27	Sec. 10. As used in this chapter, "provider facility" means any of
28	the following:
29	(1) A hospital licensed under IC 16-21-2.
30	(2) An ambulatory outpatient surgery center licensed under
31	IC 16-21-2.
32	(3) An abortion clinic licensed under IC 16-21-2.
33	(4) A birthing center licensed under IC 16-21-2.
34	(5) A facility that provides diagnostic services to the medical
35	profession or the general public.
36	(6) A laboratory where clinical pathology tests are carried out
37	on specimens to obtain information about the health of a
38	patient.
39	(7) A facility where radiologic and electromagnetic images are
40	made to obtain information about the health of a patient.
41	(8) An infusion center that administers intravenous
42	medications.



1	Sec. 11. (a) This section does not apply to a individual who is a
2	Medicaid recipient.
3	(b) An individual for whom a nonemergency health care service
4	has been ordered may request from the practitioner who will
5	provide the nonemergency health care service a good faith estimate
6	of the total price the practitioner will charge for providing the
7	nonemergency health care service.
8	(c) A practitioner who receives a request from a patient under
9	subsection (b) shall, not more than three (3) business days after
10	receiving the request, provide to the individual a good faith
11	estimate of the total price that the practitioner will charge for
12	providing the nonemergency health care service.
13	(d) A practitioner must ensure that a good faith estimate
14	provided to an individual under this section is accompanied by a
15	notice stating that:
16	(1) an estimate provided under this section is not binding on
17	the practitioner; and
18	(2) the amount the practitioner charges the individual may
19	vary from the estimate based on the individual's medical
20	needs.
21	(e) A practitioner may not charge an individual for information
22	provided under this section.
23	Sec. 12. (a) If:
24	(1) the individual who requests a good faith estimate from a
25	practitioner under this chapter is a covered individual with
26	respect to a network plan; and
27	(2) the practitioner from which the individual requests the
28	good faith estimate is in network with respect to the same
29	network plan;
30	the good faith estimate that the practitioner provides to the
31	individual under this chapter must be based on the negotiated
32	charges to which the practitioner has agreed as an in network
33	provider.
34	(b) If the individual who requests a good faith estimate from a
35	practitioner under this chapter:
36	(1) is not a covered individual with respect to any network
37	plan; or
38	(2) is not a covered individual with respect to a network plan
39	with respect to which the practitioner is in network;
40	the good faith estimate that the practitioner provides to the
41	individual under this chapter must be based on the amounts that

the practitioner charges for the nonemergency health care service $% \left(-\frac{1}{2}\right) =-\frac{1}{2}\left(-\frac{1}{2}\right) =-\frac{1}{$



1	in the absence of any network plan.
2	Sec. 13. A practitioner may provide a good faith estimate to an
3	individual under this chapter:
4	(1) in a writing delivered to the individual;
5	(2) by electronic mail; or
6	(3) through a mobile application;
7	according to the preference expressed by the individual.
8	Sec. 14. (a) A good faith estimate provided by a practitioner to
9	an individual under this chapter must:
10	(1) state the services and material items that the good faith
11	estimate is based on;
12	(2) set forth the estimated price for the services and material
13	items referred to in subdivision (1); and
14	(3) include a total figure that is a sum of the estimated prices
15	referred to in subdivision (2).
16	(b) Subsection (a) does not prohibit a practitioner from
17	providing to an individual a good faith estimate that indicates how
18	much of the total figure stated under subsection (a)(3) will be the
19	individual's out-of-pocket expense after the health carrier's
20	payment of charges.
21	(c) A health carrier must provide a practitioner with timely
22	information needed by the practitioner to comply with the
23	requirements under this chapter.
23 24	Sec. 15. If:
25	(1) a practitioner is expected to provide a nonemergency
26	health care service to an individual in a provider facility; and
27	(2) the provider facility receives a request from an individual
28	for a good faith estimate under IC 16-21-15;
29	the practitioner, upon request from the provider facility, shall
30	provide to the provider facility a good faith estimate of the
31	practitioner's charge for providing the nonemergency health care
32	service to enable the provider facility to comply with
33	IC 16-21-15-11.
34	Sec. 16. (a) A practitioner that has ordered, scheduled, or
35	referred the individual for a nonemergency health care service
36	shall provide to the individual an electronic or paper copy of a
37	written notice that states the following, or words to the same effect:
38	"A patient may at any time ask a practitioner for an estimate of the
39	amount the practitioner will charge for providing a nonemergency
10	medical service. The law requires that the estimate be provided
11	within 3 business days.".
12	(b) The state department may adopt rules under IC 4-22-2 to



1	establish requirements for practitioners to provide additional
2	charging information under this section.
3	Sec. 17. The appropriate board (as defined in IC 25-1-9-1) may
4	take action against a practitioner:
5	(1) under IC 25-1-9-9(a)(3) or IC 25-1-9-9(a)(4) for an initial
6	violation or isolated violations of this chapter; or
7	(2) under IC 25-1-9-9(a)(1), IC 25-1-9-9(a)(2), or
8	IC 25-1-9-9(a)(6) for repeated or persistent violations of this
9	chapter;
10	concerning the providing of a good faith estimate to an individual
11	for whom a nonemergency health care service has been ordered or
12	the providing of notice in the practitioner's office or on the
13	practitioner's Internet web site that a patient may at any time ask
14	for an estimate of the amount that the patient will be charged for
15	a medical service.
16	SECTION 29. IC 25-26-13-4, AS AMENDED BY P.L.5-2016,
17	SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
18	JULY 1, 2020]: Sec. 4. (a) The board may:
19	(1) adopt rules under IC 4-22-2 for implementing and enforcing
20	this chapter;
21	(2) establish requirements and tests to determine the moral,
22	physical, intellectual, educational, scientific, technical, and
23	professional qualifications for applicants for pharmacists'
24	licenses;
25	(3) refuse to issue, deny, suspend, or revoke a license or permit or
26	place on probation or fine any licensee or permittee under this
27	chapter;
28	(4) regulate the sale of drugs and devices in the state of Indiana;
29	(5) impound, embargo, confiscate, or otherwise prevent from
30	disposition any drugs, medicines, chemicals, poisons, or devices
31	which by inspection are deemed unfit for use or would be
32	dangerous to the health and welfare of the citizens of the state of
33	Indiana; the board shall follow those embargo procedures found
34	in IC 16-42-1-18 through IC 16-42-1-31, and persons may not
35	refuse to permit or otherwise prevent members of the board or
36	their representatives from entering such places and making such
37	inspections;
38	(6) prescribe minimum standards with respect to physical
39	characteristics of pharmacies, as may be necessary to the
10	maintenance of professional surroundings and to the protection of
11	the safety and welfare of the public;
12	(7) subject to IC 25-1-7, investigate complaints, subpoena



1	witnesses, schedule and conduct hearings on behalf of the public
2	interest on any matter under the jurisdiction of the board;
3	(8) prescribe the time, place, method, manner, scope, and subjects
4	of licensing examinations which shall be given at least twice
5	annually; and
6	(9) perform such other duties and functions and exercise such
7	other powers as may be necessary to implement and enforce this
8	chapter.
9	(b) The board shall adopt rules under IC 4-22-2 for the following:
10	(1) Establishing standards for the competent practice of
11	pharmacy.
12	(2) Establishing the standards for a pharmacist to counsel
13	individuals regarding the proper use of drugs.
14	(3) Establishing standards and procedures before January 1, 2006,
15	to ensure that a pharmacist:
16	(A) has entered into a contract that accepts the return of
17	expired drugs with; or
18	(B) is subject to a policy that accepts the return of expired
19	drugs of;
20	a wholesaler, manufacturer, or agent of a wholesaler or
21	manufacturer concerning the return by the pharmacist to the
22	wholesaler, the manufacturer, or the agent of expired legend drugs
23	or controlled drugs. In determining the standards and procedures,
24	the board may not interfere with negotiated terms related to cost,
25	expenses, or reimbursement charges contained in contracts
26	between parties, but may consider what is a reasonable quantity
27	of a drug to be purchased by a pharmacy. The standards and
28	procedures do not apply to vaccines that prevent influenza,
29	medicine used for the treatment of malignant hyperthermia, and
30	other drugs determined by the board to not be subject to a return
31	policy. An agent of a wholesaler or manufacturer must be
32	appointed in writing and have policies, personnel, and facilities
33	to handle properly returns of expired legend drugs and controlled
34	substances.
35	(4) The following concerning the issuance of a permit under
36	IC 25-26-14.5:
37	(A) Inspection report requirements described under
38	IC 25-26-14.5-1.
39	(B) The financial responsibility of entities that hold any
40	permit under IC 25-26-14.5.

(c) The board may grant or deny a temporary variance to a rule it



41

42

has adopted if:

1	(1) the board has adopted rules which set forth the procedures and
2	standards governing the grant or denial of a temporary variance;
3	and
4	(2) the board sets forth in writing the reasons for a grant or denial
5	of a temporary variance.
6 7	(d) The board shall adopt rules and procedures, in consultation with the medical licensing board, concerning the electronic transmission of
8	prescriptions. The rules adopted under this subsection must address the
9	following:
10	(1) Privacy protection for the practitioner and the practitioner's
11	patient.
12	(2) Security of the electronic transmission.
13	(3) A process for approving electronic data intermediaries for the
14	electronic transmission of prescriptions.
15	(4) Use of a practitioner's United States Drug Enforcement
16	Agency registration number.
17	(5) Protection of the practitioner from identity theft or fraudulent
18	use of the practitioner's prescribing authority.
19	(e) The governor may direct the board to develop:
20	(1) a prescription drug program that includes the establishment of
21	criteria to eliminate or significantly reduce prescription fraud; and
22	(2) a standard format for an official tamper resistant prescription
23	drug form for prescriptions (as defined in IC 16-42-19-7(1)).
24	The board may adopt rules under IC 4-22-2 necessary to implement
25	this subsection.
26	(f) The standard format for a prescription drug form described in
27	subsection (e)(2) must include the following:
28	(1) A counterfeit protection bar code with human readable
29	representation of the data in the bar code.
30	(2) A thermochromic mark on the front and the back of the
31	prescription that:
32	(A) is at least one-fourth (1/4) of one (1) inch in height and
33	width; and
34	(B) changes from blue to clear when exposed to heat.
35	(g) The board may contract with a supplier to implement and
36	manage the prescription drug program described in subsection (e). The
37	supplier must:
38	(1) have been audited by a third party auditor using the SAS 70
39	audit or an equivalent audit for at least the three (3) previous
40	years; and
41	(2) be audited by a third party auditor using the SAS 70 audit or

an equivalent audit throughout the duration of the contract;



1	in order to be considered to implement and manage the program.
2	(h) The board shall adopt rules under IC 4-22-2, or emergency rules
3	in the manner provided under IC 4-22-2-37.1 that take effect on July 1,
4	2016, concerning:
5	(1) professional determinations made under IC 35-48-4-14.7(d);
6	and
7	(2) the determination of a relationship on record with the
8	pharmacy under IC 35-48-4-14.7.
9	(i) The board may:
10	(1) review professional determinations made by a pharmacist; and
11	(2) take appropriate disciplinary action against a pharmacist who
12	violates a rule adopted under subsection (h) concerning a
13	professional determination made;
14	under IC 35-48-4-14.7 concerning the sale of ephedrine and
15	pseudoephedrine.
16	SECTION 30. IC 25-26-13-29, AS AMENDED BY P.L.209-2018,
17	SECTION 10, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
18	JULY 1, 2020]: Sec. 29. (a) It is unlawful:
19	(1) For any person to display or permit to be displayed, a
20	pharmacy permit in any facility or place of business other than
21	that for which it was issued.
22	(2) For any person to accept a prescription for filling or
23	compounding at any place or facility for which there is not a valid
24	pharmacy permit.
25	(3) For any person to operate a pharmacy or to take, assume,
26	exhibit, display, or advertise by any medium, the title "drugs",
27	"prescriptions", "medicine", "drug store", "pharmacy", or
28	"apothecary shop", or any combination of such titles or any other
29	title, symbol, term, or description of like import intended to cause
30	the public to believe that it is a pharmacy unless the person holds
31	a valid pharmacy permit.
32	(4) For any person to engage or offer to engage in the practice of
33	pharmacy or to hold himself or herself out as a pharmacist
34	without a valid pharmacist's license that is classified as active by
35	the board.
36	(b) A person who violates a provision of subsection (a) commits a
37	Level 6 felony.
38	(c) Nothing in this chapter shall apply to, nor in any manner
39	interfere with the business of a general merchant in selling and

distributing nonnarcotic, nonprescription medicines or drugs which are

prepackaged, fully prepared by the manufacturer for use by the

consumer, and labeled in accordance with the requirements of the state



40

41

1	and federal food and drug acts.
2	(d) This chapter does not apply to, or in any manner interfere with,
3	the business of a manufacturer in selling and delivering a dialysate
4	drug or a device that is necessary for home peritoneal renal dialysis for
5	a patient who has end stage renal disease if all of the following apply:
6	(1) The dialysate drug or device is approved by the federal Food
7	and Drug Administration under federal law.
8	(2) The dialysate drug or device is held by the manufacturer, a
9	third party logistics provider, or a wholesale drug distributor in
10	accordance with the requirements of IC 25-26-14.
11	(3) The dialysate drug or device is delivered in the manufacturer's
12	original, sealed packaging.
13	(4) The dialysate drug or device is delivered only upon:
14	(A) receipt of a physician's prescription by a pharmacy that
15	holds a pharmacy permit under this chapter; and
16	(B) the transmittal of an order from the pharmacy described in
17	clause (A) to the manufacturer, third party logistics provider,
18	or wholesale drug distributor.
19	(5) The manufacturer, third party logistics provider, or wholesale
20	drug distributor delivers the dialysate drug or device directly to:
21	(A) the patient or the patient's designee for self-administration
22	of the dialysis therapy; or
23	(B) a health care provider for administration of the dialysis
24	therapy to the patient.
25	(e) This chapter does not apply to the purchase of prescription
26	drugs through and in compliance with the importation of
27	prescription drugs program established under IC 16-47-3.
28	SECTION 31. IC 25-26-14-17.8, AS AMENDED BY P.L.98-2006,
29	SECTION 22, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
30	JULY 1, 2020]: Sec. 17.8. (a) This section does not apply to
31	purchase of prescription drugs through and in compliance with the
32	importation of prescription drugs program established under
33	IC 16-47-3. A wholesale drug distributor licensed under this chapter
34	that purchases legend drugs from a wholesale drug distributor that is
35	not licensed under this chapter shall act with due diligence as required
36	under this section and rules adopted by the board. However, the due
37	diligence requirements of this section do not apply to purchases from
38	an unlicensed wholesale drug distributor that has obtained
39	accreditation through the National Association of Boards of Pharmacy's
40	Verified-Accredited Wholesale Distributors program.

(b) Before the initial purchase of legend drugs from the unlicensed

wholesale drug distributor, the licensed wholesale drug distributor shall



41

1	obtain the following information from the unlicensed wholesale drug
2	distributor:
3	(1) A list of states in which the unlicensed wholesale drug
4	distributor is licensed.
5	(2) A list of states into which the unlicensed wholesale drug
6	distributor ships legend drugs.
7	(3) Copies of all state and federal regulatory licenses and
8	registrations held by the unlicensed wholesale drug distributor.
9	(4) The unlicensed wholesale drug distributor's most recent
10	facility inspection reports.
l 1	(5) Information regarding general and product liability insurance
12	maintained by the unlicensed wholesale drug distributor,
13	including copies of relevant policies.
14	(6) A list of other names under which the unlicensed wholesale
15	drug distributor does business or has been previously known.
16	(7) A list of corporate officers and managerial employees of the
17	unlicensed wholesale drug distributor.
18	(8) A list of all owners of the unlicensed wholesale drug
19	distributor that own more than ten percent (10%) of the
20	unlicensed wholesale drug distributor, unless the unlicensed
21	wholesale drug distributor is publicly traded.
22 23 24	(9) A list of all disciplinary actions taken against the unlicensed
23	wholesale drug distributor by state and federal agencies.
24	(10) A description, including the address, dimensions, and other
25	relevant information, of each facility used by the unlicensed
26	wholesale drug distributor for legend drug storage and
27	distribution.
28	(11) A description of legend drug import and export activities of
29	the unlicensed wholesale drug distributor.
30	(12) A description of the unlicensed wholesale drug distributor's
31	procedures to ensure compliance with this chapter.
32	(13) A statement:
33	(A) as to whether; and
34	(B) of the identity of each manufacturer for which;
35	the unlicensed wholesale drug distributor is an authorized
36	distributor.
37	(c) Before the initial purchase of legend drugs from an unlicensed
38	wholesale drug distributor, the licensed wholesale drug distributor
39	shall:
10	(1) request that the board obtain and consider the results of a
11 12	national criminal history background check (as defined in
12	IC 10-13-3-12) through the state police department of all



1	individuals associated with the unlicensed wholesale drug
2	distributor as specified for licensure of a wholesale drug
3	distributor under section 16(b) of this chapter; and
4	(2) verify the unlicensed wholesale drug distributor's status as an
5	authorized distributor, if applicable.
6	(d) If an unlicensed wholesale drug distributor's facility has not beer
7	inspected by the board or the board's agent within three (3) years after
8	a contemplated purchase described in subsection (a), the licensed
9	wholesale drug distributor shall conduct an inspection of the
10	unlicensed wholesale drug distributor's facility:
11	(1) before the initial purchase of legend drugs from the unlicensed
12	wholesale drug distributor; and
13	(2) at least once every three (3) years unless the unlicensed
14	wholesale drug distributor's facility has been inspected by the
15	board, or the board's agent, during the same period;
16	to ensure compliance with applicable laws and regulations relating to
17	the storage and handling of legend drugs. A third party may be engaged
18	to conduct the site inspection on behalf of the licensed wholesale drug
19	distributor.
20	(e) At least annually, a licensed wholesale drug distributor tha
21	purchases legend drugs from an unlicensed wholesale drug distributor
22	shall ensure that the unlicensed wholesale drug distributor maintains
23	a record keeping system that meets the requirements of section 17(3)
24	of this chapter.
25	(f) If a licensed wholesale drug distributor that purchases legend
26	drugs from an unlicensed wholesale drug distributor has reason to
27	believe that a legend drug purchased from the unlicensed wholesale
28	drug distributor is misbranded, adulterated, counterfeit, or suspected
29	counterfeit, the licensed wholesale drug distributor shall conduct a for
30	cause authentication of each distribution of the legend drug back to the
31	manufacturer.
32	(g) An unlicensed wholesale drug distributor that has engaged in the
33	distribution of a legend drug for which a licensed wholesale drug
34	distributor conducts a for cause authentication under subsection (f
35	shall provide, upon request, detailed information regarding the
36	distribution of the legend drug, including the:
37	(1) date of purchase of the legend drug;
38	(2) lot number of the legend drug;
39	(3) sales invoice number of the legend drug; and
40	(4) contact information, including name, address, telephone
41	number, and any electronic mail address of the unlicensed
42	wholesale drug distributor that sold the legend drug.



	37
1	(h) If a licensed wholesale drug distributor conducts a for cause
2	authentication under subsection (f) and is unable to authenticate each
3	distribution of the legend drug, the licensed wholesale drug distributor
4	shall quarantine the legend drug and report the circumstances to the
5	board and the federal Food and Drug Administration within ten (10)
6	business days after completing the attempted authentication.
7	(i) If a licensed wholesale drug distributor authenticates the
8	distribution of a legend drug back to the manufacturer under subsection
9	(f), the licensed wholesale drug distributor shall maintain records of the
10	authentication for three (3) years and shall provide the records to the
11	board upon request.
12	(j) A licensed wholesale drug distributor that purchases legend
13	drugs from an unlicensed wholesale drug distributor shall, at least
14	annually, conduct random authentications of required pedigrees on at
15	least ten percent (10%) of sales units of distributions of legend drugs
16	that were purchased from unlicensed wholesale drug distributors.
17	(k) An unlicensed wholesale drug distributor from which a licensed
18	wholesale drug distributor has purchased legend drugs shall cooperate

- wholesale drug distributor has purchased legend drugs shall cooperate with the random authentications of pedigrees under this section and provide requested information in a timely manner.
- (1) If a wholesale drug distributor conducts a random authentication under subsection (j) and is unable to authenticate each distribution of the legend drug, the wholesale drug distributor shall quarantine the legend drug and report the circumstances to the board and the federal Food and Drug Administration not more than ten (10) business days after completing the attempted authentication.
- SECTION 32. IC 25-26-14.5 IS ADDED TO THE INDIANA CODE AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]:
- Chapter 14.5. International Export Pharmacy Permit and Wholesale Drug Distributor Permit
- Sec. 1. (a) To participate as an exporter of prescription drugs into Indiana under the importation of prescription drugs program established by IC 16-47-3-5, a pharmacy located outside the United States must meet the following requirements:
 - (1) Hold an international export pharmacy permit issued under this chapter.
 - (2) Maintain at all times an active and unencumbered license or permit to operate a pharmacy:
 - (A) in compliance with the laws and rules of the jurisdiction in which the pharmacy is located and from which the prescription drugs will be exported; and



19

20

21

22

23

24

25

26 27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

1	(B) in a country with which the United States has a current
2	mutual recognition agreement, cooperation agreement,
3	memorandum of understanding, or other federal
4	mechanism recognizing the country's adherence to current
5	good manufacturing practices for pharmaceutical
6	products.
7	(3) Submit an application for an international export
8	pharmacy permit on a form developed and provided by the
9	board.
10	(b) An applicant for an international export pharmacy permit
11	must submit the following to the board with the application
12	required under subsection (a)(3):
13	(1) Proof of an active and unencumbered license or permit to
14	operate a pharmacy in compliance with the laws and rules of
15	the jurisdiction in which the dispensing facility is located and
16	from which the prescription drugs will be exported.
17	(2) Documentation demonstrating that the country in which
18	the pharmacy operates has a current mutual recognition
19	agreement, cooperation agreement, memorandum of
20	understanding, or other federal mechanism recognizing the
21	country's adherence to current good manufacturing practices
22	for pharmaceutical products.
23	(3) The location, names, and title of all principal corporate
24	officers and the pharmacist who serves as the prescription
25	department manager for prescription drugs exported into
26	Indiana under the importation of prescription drugs program.
27	(4) A written attestation by an owner or officer of the
28	applicant and by the applicant's prescription drug manager
29	containing the following affirmations:
30	(A) That the individual has read and understands the laws
31	and rules governing the manufacture, distribution, and
32	dispensing of prescription drugs in Indiana.
33	(B) That prescription drugs shipped, mailed, or delivered
34	into Indiana:
35	(i) will meet or exceed Indiana's standards for safety and
36	efficacy; and
37	(ii) will not have been, and may not be, manufactured or
38	distributed in violation of the laws and rules of the
39	jurisdiction in which the applicant is located and from
40	which the prescription drugs will be exported.
41	(5) A current inspection report from an inspection conducted

by the regulatory or licensing agency of the jurisdiction in



1	which the applicant is located. The inspection report must
2	reflect compliance with this section. An inspection report is
3	current if the inspection was conducted not earlier than six (6)
4	months before the submission of the application for an initial
5	permit or not earlier than one (1) year for the renewal of a
6	permit.
7	(c) If an applicant is not able to submit an inspection report that
8	meets the requirements of subsection (b)(5), the board must do one
9	(1) of the following:
10	(1) Conduct, or contract with a person to conduct, an onsite
11	inspection at the cost of the applicant.
12	(2) Accept a current inspection report from an entity that:
13	(A) meets requirements adopted by the board under
14	IC 4-22-2 for entities to perform inspections; and
15	(B) has been approved by the board.
16	(3) Accept a current inspection report from the United States
17	Food and Drug Administration conducted under the federal
18	Drug Quality and Security Act.
19	Sec. 2. To participate as an exporter of prescription drugs into
20	Indiana under the importation of prescription drugs program
21	established by IC 16-47-3, a nonresident prescription drug
22	manufacturer located outside the United States must register with
23	the board and obtain the international export pharmacy permit
24	under this chapter.
25	Sec. 3. (a) The board shall adopt rules under IC 4-22-2
26	governing the financial responsibility of a pharmacy that holds a
27	permit under this chapter. The rules must include at least the
28	following:
29	(1) Financial reporting requirements.
30	(2) Standards for financial capability to perform the functions
31	governed by the permit.
32	(3) Requirements for ensuring that the permit holder and the
33	permit holder's contractors can be held accountable for the
34	financial consequences of any act of malfeasance or
35	misfeasance or fraudulent or dishonest acts committed by the
36	permit holder or the permit holder's contractors.
37	(b) The board shall adopt rules under IC 4-22-2 concerning
38	inspection report requirements described in section 1 of this
39	chapter.
40	Sec. 4. (a) A wholesale drug distributor located outside the
41	United States must obtain an international prescription drug

wholesale drug distributor permit under this chapter to engage in



1	the wholesale exportation and distribution of prescription drugs in
2	Indiana under the importation of prescription drugs program
3	established by IC 16-47-3-5.
4	(b) A wholesale drug distributor must meet the following in
5	order to obtain a wholesale drug distributor permit:
6	(1) Be licensed or permitted to operate in a country with
7	which the United States has:
8	(A) a current mutual recognition agreement;
9	(B) a current cooperation agreement;
10	(C) a current memorandum of understanding; or
11	(D) another federal mechanism recognizing the country's
12	adherence to current good manufacturing practices for
13	pharmaceutical products.
14	(2) Maintain at all times a license or permit to engage in the
15	wholesale distribution of prescription drugs in compliance
16	with the laws and rules of the jurisdiction in which the
17	wholesale drug distributor operates.
18	(c) The board shall adopt rules under IC 4-22-2 governing the
19	financial responsibility of a wholesale drug distributor that holds
20	a permit under this chapter. The rules must include at least the
21	following:
22	(1) Financial reporting requirements.
23	(2) Standards for financial capability to perform the functions
24	governed by the permit.
25	(3) Requirements for ensuring that a wholesale drug
26	distributor holding a permit under this chapter and the
27	wholesale drug distributor's contractors are held accountable
28	for the financial consequences of any act of malfeasance or
29	misfeasance or fraudulent or dishonest acts committed by the
30	permit holder or the permit holder's contractors.
31	SECTION 33. IC 27-1-15.6-13.5 IS ADDED TO THE INDIANA
32	CODE AS A NEW SECTION TO READ AS FOLLOWS
33	[EFFECTIVE JULY 1, 2020]: Sec. 13.5. (a) An insurance producer
34	shall disclose to any prospective and current clients on a separate
35	written notification any commission, service fee, brokerage fee, or
36	other valuable consideration, including whether the amount is
37	based on a percentage of total plan premiums or a flat per member
38	fee, concerning:
39	(1) a health insurance contract that is signed directly with the
40	insurance producer; or

(2) a health insurance contract signed with a third party

administrator or insurer that will compensate the insurance



41

1	producer.
2	(b) A copy of the written notification required under this section
3	must be signed by the client.
4	SECTION 34. IC 27-1-37-7 IS ADDED TO THE INDIANA CODE
5	AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY
6	1, 2020]: Sec. 7. (a) This section applies to:
7	(1) health provider contracts; and
8	(2) contracts between a provider and a pharmacy benefits
9	manager;
10	entered into or renewed, including contracts that automatically
11	renew after the expiry date, after June 30, 2020.
12	(b) A health provider contract may not contain a provision that
13	prohibits the disclosure of health care service claims data to
14	employers providing the coverage. However, any disclosure of
15	claims data must comply with health privacy laws, including the
16	federal Health Insurance Portability and Accountability Ac
17	(HIPAA) (P.L. 104-191).
18	(c) A violation of this section constitutes an unfair or deceptive
19	act or practice in the business of insurance under IC 27-4-1-4.
20	SECTION 35. IC 27-1-45 IS ADDED TO THE INDIANA CODE
21	AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE
22	UPON PASSAGE]:
23	Chapter 45. All Payer Claims Data Base
24	Sec. 1. As used in this chapter, "data base" refers to the al
25	payer claims data base created under this chapter.
26	Sec. 2. As used in this chapter, "health payer" includes the
27	following:
28	(1) Medicare.
29	(2) Medicaid or a managed care organization (as defined in
30	IC 12-7-2-126.9) that has contracted with Medicaid to provide
31	services to a Medicaid recipient.
32	(3) An insurer that issues a policy of accident and sickness
33	insurance (as defined in IC 27-8-5-1).
34	(4) A health maintenance organization (as defined in
35	IC 27-13-1-19).
36	(5) A pharmacy benefit manager (as defined in
37	IC 27-1-24.8-3).
38	(6) A third party administrator.
39	(7) An insurer (as defined in IC 27-1-26-1), excluding insurers
40	of life insurance.
41	(8) Any other person identified by the commissioner for
42	participation in the data base described in this chapter.



1	Sec. 3. (a) Before July 1, 2020, the department shall issue a
2	request for information in compliance with IC 5-23-4.5 concerning
3	the creation, operation, and maintenance of a data base.
4	(b) The request for information must include the following
5	questions:
6	(1) How the person would collect all relevant claims data for
7	the data base from a health payer in a manner that would
8	minimize technical barriers for a health payer to submit a
9	claim.
10	(2) How the person would promote and encourage self funded
11	plans to voluntarily submit claims data for inclusion in the
12	data base.
13	(3) What funding sources the person would seek to offset costs
14	to implement and maintain the data base.
15	(4) How the person would make data from the data base
16	available, including what sufficient fee would need to be
17	assessed, to researchers, companies, and other interested
18	parties in analyzing the data.
19	(5) How the person would ensure the following:
20	(A) That data is submitted and released in a
21	machine-readable format.
22	(B) That the data from the data base is used in an ethical
23	manner.
24	(C) That the data is not personally identifiable and is
25	properly secured and maintained, and that the person
26	complies with federal and state health care privacy laws.
27	(6) How the person would establish a public web portal for
28	individuals to quickly and easily compare prices for the full
29	spectrum of medical billing codes as well as check quality
30	ratings of providers.
31	(7) What threshold should be set for health payers to submit
32	data for the data base.
33	(8) How the person would work with other states and relevant
34	stakeholders to either:
35	(A) use a data language that is already available; or
36	(B) facilitate the establishment of a common data language
37	to be used by states for the data.
38	(9) Whether any changes to state law would increase the
39	functionality and effectiveness of the data base and
40	recommendations of the statutes and necessary changes.
41	(10) Whatever other questions the department determines is

relevant to the implementation of a robust and transparent



1	data base.
2 3	(c) The department shall set the deadline for submissions of the
	request for information under this section that may be not later
4	than November 30, 2020.
5	Sec. 4. (a) After May 30, 2021, but before June 15, 2021, the
6	department shall issue a request for proposals for a person to
7	create, operate, and maintain the data base under this chapter. In
8	addition to the requirements of IC 5-22-9, the request for proposals
9	must include the considerations contained in the request for
10	information under section 3 of this chapter.
11	(b) The request for proposals must state that the data base's
12	purpose is to facilitate the following:
13	(1) Identifying health care needs and informing health care
14	policy.
15	(2) Comparing costs between various treatment settings and
16	approaches.
17	(3) Providing information to consumers and purchasers of
18	health care.
19	(4) Improving the quality and affordability of patient health
20	care and health care coverage.
21	(c) Submissions for the request for proposals under this section
22	must occur not later than September 30, 2021.
23	(d) The department shall publish the department's decision
24	concerning the submissions not later than November 30, 2021.
25	(e) If the department accepts a submission for the request for
26	proposals, the department shall enter into a contract with the
27	person to act as administrator of the data base and develop the
28	data base not later than June 30, 2022.
29	(f) The administrator shall ensure that the data base is secure
30	and compliant with the federal Health Insurance Portability and
31	Accountability Act (HIPAA).
32	Sec. 5. A health payer shall begin submitting the required data
33	in a format specified by the administrator of the data base not later
34	than three (3) months from the first day the department declares
35	the data base to be fully operational.
36	SECTION 36. IC 27-2-25 IS ADDED TO THE INDIANA CODE
37	AS A NEW CHAPTER TO READ AS FOLLOWS [EFFECTIVE
38	JULY 1, 2020]:
39	Chapter 25. Health Carrier Good Faith Estimates
40	Sec. 1. As used in this chapter, "coverage" means the right of an
41	individual to receive:
42	(1) health care services; or



1	(2) payment or reimbursement for health care services;
2	from a health carrier.
3	Sec. 2. As used in this chapter, "covered individual" means an
4	individual who is entitled to coverage from a health carrier.
5	Sec. 3. As used in this chapter, "good faith estimate" means a
6	health carrier's reasonable estimate of:
7	(1) the amount of the cost of a nonemergency health care
8	service that the health carrier will:
9	(A) pay for; or
10	(B) reimburse to;
11	a covered individual; or
12	(2) the extent and nature of the nonemergency health care
13	service a covered individual is entitled to receive;
14	that a health carrier provides upon request to a covered individual
15	for whom a nonemergency health care service has been ordered.
16	Sec. 4. (a) As used in this chapter, "health carrier" means an
17	entity:
18	(1) that is subject to this title and the administrative rules
19	adopted under this title; and
20	(2) that enters into a contract to:
21	(A) provide health care services;
22	(B) deliver health care services;
23	(C) arrange for health care services; or
24	(D) pay for or reimburse any of the costs of health care
25	services.
26	(b) The term includes the following:
27	(1) An insurer, as defined in IC 27-1-2-3(x), that issues a
28	policy of accident and sickness insurance, as defined in
29	IC 27-8-5-1(a).
30	(2) A health maintenance organization, as defined in
31	IC 27-13-1-19.
32	(3) An administrator (as defined in IC 27-1-25-1(a)) that is
33	licensed under IC 27-1-25.
34	(4) Any other entity that provides a plan of health insurance,
35	health benefits, or health care services.
36	Sec. 5. As used in this chapter, "in network", when used in
37	reference to a practitioner, means that the health care services
38	provided by the practitioner are subject to a health carrier's
39	network plan.
40	Sec. 6. (a) As used in this chapter, "network" means a group of
41	provider facilities and practitioners that:
42	(1) provide health care services to covered individuals; and



1	(2) have agreed to, or are otherwise subject to, maximum
2	limits on the fees and charges for the health care services to be
3	provided to the covered individuals.
4	(b) The term includes the following:
5	(1) A network described in subsection (a) that is established
6	pursuant to a contract between an insurer providing coverage
7	under a group health policy and:
8	(A) individual provider facilities and practitioners;
9	(B) a preferred provider organization; or
10	(C) an entity that employs or represents providers,
11	including:
12	(i) an independent practice association; and
13	(ii) a physician-hospital organization.
14	(2) A health management organization, as defined in
15	IC 27-13-1-19.
16	Sec. 7. As used in this chapter, "network plan" means a plan of
17	a health carrier that:
18	(1) requires a covered person to receive; or
19	(2) creates incentives, including financial incentives, for a
20	covered person to receive;
21	health care services from one (1) or more providers that are under
22	contract with, managed by, or owned by the health carrier.
22 23 24	Sec. 8. (a) As used in this chapter, "nonemergency health care
24	service" means a service or series of services ordered, scheduled,
25	or referred by a practitioner for the:
26	(1) diagnosis;
27	(2) prevention;
28	(3) treatment;
29	(4) cure; or
30	(5) relief;
31	of a physical, mental, or behavioral health condition, illness, injury,
32	or disease that is not provided on an emergency basis.
33	Sec. 9. As used in this chapter, "practitioner" means:
34	(1) an individual who holds a license, certificate, registration,
35	or permit under:
36	(A) IC 25-22.5 (physicians);
37	(B) IC 25-27 (physical therapists); or
38	(C) IC 25-33 (psychologists); or
39	(2) an organization consisting of or employing two (2) or more
40	individuals described in subdivision (1).
41	Sec. 9.5. As used in this chapter, "price" means the negotiated
12	rate hetween the



1	(1) provider facility and practitioner; and
2	(2) covered individual's health carrier;
3	minus the amount that the health carrier will pay.
4	Sec. 10. As used in this chapter, "provider" means:
5	(1) a provider facility; or
6	(2) a practitioner.
7	Sec. 11. As used in this chapter, "provider facility" means any of
8	the following:
9	(1) A hospital licensed under IC 16-21-2.
10	(2) An ambulatory outpatient surgery center licensed under
11	IC 16-21-2.
12	(3) An abortion clinic licensed under IC 16-21-2.
13	(4) A birthing center licensed under IC 16-21-2.
14	(5) A facility that provides diagnostic services to the medical
15	profession or the general public.
16	(6) A laboratory where clinical pathology tests are carried out
17	on specimens to obtain information about the health of a
18	patient.
19	(7) A facility where radiologic and electromagnetic images are
20	made to obtain information about the health of a patient.
21	(8) An infusion center that administers intravenous
22	medications.
23	Sec. 12. (a) A covered individual for whom a nonemergency
24	health care service has been ordered may request from the health
25	carrier a good faith estimate of:
26	(1) the amount of the cost of the nonemergency health care
27	service that the health carrier will:
28	(A) pay for; or
29	(B) reimburse to;
30	the covered individual; or
31	(2) the extent and nature of the ordered nonemergency health
32	care service a covered individual is entitled to receive from
33	the health carrier.
34	(b) If:
35	(1) a health carrier provides coverage to a covered individual
36	through a network plan; and
37	(2) the health carrier receives a request for a good faith
38	estimate from a covered individual for whom a nonemergency
39	health care service has been ordered;
40	the health carrier shall inform the covered individual whether the
41	provider facility in which the nonemergency health care service
42	will be provided is in network and whether each scheduled



1	practitioner who will provide the nonemergency health care
2	service is in network.
3	(c) A health carrier that receives a request from a covered
4	individual patient under subsection (b) shall, not more than three
5	(3) business days after receiving the request, provide to the
6	individual a good faith estimate as described in section 14 of this
7	chapter.
8	(d) A health carrier must ensure that a good faith estimate
9	provided to an individual under this section is accompanied by a
10	notice stating that:
11	(1) the amount that the health carrier will:
12	(A) pay; or
13	(B) reimburse;
14	for or to the covered individual for the nonemergency health
15	care services the individual receives; and
16	(2) the nature and extent of the nonemergency health care
17	services the individual will receive;
18	may vary from the health carrier's good faith estimate based on
19	the individual's medical needs.
20	(e) A health carrier may not charge an individual for
21	information provided under this section.
22	(f) A practitioner and provider facility must provide a health
23	carrier with timely information needed by the health carrier to
24	comply with the requirements under this chapter.
25	Sec. 13. A health carrier may provide a good faith estimate to an
26	individual under this chapter:
27	(1) in a writing delivered to the individual; or
28	(2) by electronic mail;
29	according to the preference expressed by the individual.
30	Sec. 14. (a) A good faith estimate provided by a health carrier
31	to an individual under this chapter must:
32	(1) in the case of an insurer or another health carrier that
33	pays or reimburses the cost of health care services:
34	(A) state the services and material items that the good faith
35	estimate is based on;
36	(B) set forth for the services and material items referred to
37	in clause (A) the amount that the health carrier will:
38	(i) pay; or
39	(ii) reimburse;
40	for or to the covered individual for the service or material
41	item;
42	(C) include a total figure that is a sum of the amounts



1	referred to in clause (B); and
2	(D) state the out-of-pocket costs the covered individual will
3	incur, if any, beyond the amount that the health carrier
4	will pay or reimburse; and
5	(2) in the case of a health maintenance organization or
6	another health carrier that provides health care services:
7	(A) state the nature and extent of the health care services
8	to which the covered individual is entitled; and
9	(B) state the out-of-pocket costs the covered individual will
10	incur, if any, beyond being provided the health care
11	services referred to in clause (A).
12	(b) A practitioner and provider facility must provide a health
13	carrier with timely information needed by the health carrier
14	comply to with the requirements under this chapter.
15	Sec. 15. A health carrier that provides an Internet web site for
16	the use of its covered individuals shall ensure that the Internet web
17	site includes a printed notice that:
18	(1) is designed, lettered, and featured on the Internet web site
19	so as to be conspicuous to and readable by any individual with
20	normal vision who visits the Internet web site; and
21	(2) states the following, or words to the same effect: "A
22	covered individual may at any time ask the health carrier for
23 24 25	an estimate of the amount the health carrier will pay for or
24	reimburse to a covered individual for nonemergency health
25	care services that have been ordered for the covered
26	individual or the nature and extent of the ordered
27	nonemergency health care services a covered individual is
28	entitled to receive from the health carrier. The law requires
29	that an estimate be provided within 3 business days.".
30	Sec. 16. (a) If a health carrier fails or refuses:
31	(1) to provide a good faith estimate as required by this
32	chapter; or
33	(2) to provide notice on the health carrier's Internet web site
34	as required by section 15 of this chapter;
35	the insurance commissioner may, after notice and hearing under
36	IC 4-21.5, impose on the health carrier a civil penalty of not more
37	than one thousand dollars (\$1,000) for each day of noncompliance.
38	(b) A civil penalty collected under this section shall be deposited
39	in the department of insurance fund established by IC 27-1-3-28.
40	SECTION 37. IC 27-4-1-4, AS AMENDED BY P.L.124-2018,
41	SECTION 64, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
42	JULY 1, 2020]: Sec. 4. (a) The following are hereby defined as unfair



1	methods of competition and unfair and deceptive acts and practices in
2	the business of insurance:
3	(1) Making, issuing, circulating, or causing to be made, issued, or
4	circulated, any estimate, illustration, circular, or statement:
5	(A) misrepresenting the terms of any policy issued or to be
6	issued or the benefits or advantages promised thereby or the
7	dividends or share of the surplus to be received thereon;
8	(B) making any false or misleading statement as to the
9	dividends or share of surplus previously paid on similar
10	policies;
11	(C) making any misleading representation or any
12	misrepresentation as to the financial condition of any insurer,
13	or as to the legal reserve system upon which any life insurer
14	operates;
15	(D) using any name or title of any policy or class of policies
16	misrepresenting the true nature thereof; or
17	(E) making any misrepresentation to any policyholder insured
18	in any company for the purpose of inducing or tending to
19	induce such policyholder to lapse, forfeit, or surrender the
20	policyholder's insurance.
21	(2) Making, publishing, disseminating, circulating, or placing
22	before the public, or causing, directly or indirectly, to be made,
23	published, disseminated, circulated, or placed before the public,
24	in a newspaper, magazine, or other publication, or in the form of
25	a notice, circular, pamphlet, letter, or poster, or over any radio or
26	television station, or in any other way, an advertisement,
27	announcement, or statement containing any assertion,
28	representation, or statement with respect to any person in the
29	conduct of the person's insurance business, which is untrue,
30	deceptive, or misleading.
31	(3) Making, publishing, disseminating, or circulating, directly or
32	indirectly, or aiding, abetting, or encouraging the making,
33	publishing, disseminating, or circulating of any oral or written
34	statement or any pamphlet, circular, article, or literature which is
35	false, or maliciously critical of or derogatory to the financial
36	condition of an insurer, and which is calculated to injure any
37	person engaged in the business of insurance.
38	(4) Entering into any agreement to commit, or individually or by
39	a concerted action committing any act of boycott, coercion, or
40	intimidation resulting or tending to result in unreasonable
41	restraint of, or a monopoly in, the business of insurance.
42	(5) Filing with any supervisory or other public official, or making,



publishing, disseminating, circulating, or delivering to any person, or placing before the public, or causing directly or indirectly, to be made, published, disseminated, circulated, delivered to any person, or placed before the public, any false statement of financial condition of an insurer with intent to deceive. Making any false entry in any book, report, or statement of any insurer with intent to deceive any agent or examiner lawfully appointed to examine into its condition or into any of its affairs, or any public official to which such insurer is required by law to report, or which has authority by law to examine into its condition or into any of its affairs, or, with like intent, willfully omitting to make a true entry of any material fact pertaining to the business of such insurer in any book, report, or statement of such insurer.

- (6) Issuing or delivering or permitting agents, officers, or employees to issue or deliver, agency company stock or other capital stock, or benefit certificates or shares in any common law corporation, or securities or any special or advisory board contracts or other contracts of any kind promising returns and profits as an inducement to insurance.
- (7) Making or permitting any of the following:
 - (A) Unfair discrimination between individuals of the same class and equal expectation of life in the rates or assessments charged for any contract of life insurance or of life annuity or in the dividends or other benefits payable thereon, or in any other of the terms and conditions of such contract. However, in determining the class, consideration may be given to the nature of the risk, plan of insurance, the actual or expected expense of conducting the business, or any other relevant factor.
 - (B) Unfair discrimination between individuals of the same class involving essentially the same hazards in the amount of premium, policy fees, assessments, or rates charged or made for any policy or contract of accident or health insurance or in the benefits payable thereunder, or in any of the terms or conditions of such contract, or in any other manner whatever. However, in determining the class, consideration may be given to the nature of the risk, the plan of insurance, the actual or expected expense of conducting the business, or any other relevant factor.
 - (C) Excessive or inadequate charges for premiums, policy fees, assessments, or rates, or making or permitting any unfair discrimination between persons of the same class involving



1	essentially the same hazards, in the amount of premiums,
2	policy fees, assessments, or rates charged or made for:
3	(i) policies or contracts of reinsurance or joint reinsurance,
4	or abstract and title insurance;
5	(ii) policies or contracts of insurance against loss or damage
6	to aircraft, or against liability arising out of the ownership.
7	maintenance, or use of any aircraft, or of vessels or craft,
8	their cargoes, marine builders' risks, marine protection and
9	indemnity, or other risks commonly insured under marine
10	as distinguished from inland marine, insurance; or
11	(iii) policies or contracts of any other kind or kinds of
12	insurance whatsoever.
13	However, nothing contained in clause (C) shall be construed to
14	apply to any of the kinds of insurance referred to in clauses (A)
15	and (B) nor to reinsurance in relation to such kinds of insurance.
16	Nothing in clause (A), (B), or (C) shall be construed as making or
17	permitting any excessive, inadequate, or unfairly discriminatory
18	charge or rate or any charge or rate determined by the department
19	or commissioner to meet the requirements of any other insurance
20	rate regulatory law of this state.
21	(8) Except as otherwise expressly provided by law, knowingly
22	permitting or offering to make or making any contract or policy
23	of insurance of any kind or kinds whatsoever, including but not in
24	limitation, life annuities, or agreement as to such contract or
25	policy other than as plainly expressed in such contract or policy
26	issued thereon, or paying or allowing, or giving or offering to pay
27	allow, or give, directly or indirectly, as inducement to such
28	insurance, or annuity, any rebate of premiums payable on the
29	contract, or any special favor or advantage in the dividends,
30	savings, or other benefits thereon, or any valuable consideration
31	or inducement whatever not specified in the contract or policy; or
32	giving, or selling, or purchasing or offering to give, sell, or
33	purchase as inducement to such insurance or annuity or in
34	connection therewith, any stocks, bonds, or other securities of any
35	insurance company or other corporation, association, limited
36	liability company, or partnership, or any dividends, savings, or
37	profits accrued thereon, or anything of value whatsoever not
38	specified in the contract. Nothing in this subdivision and
39	subdivision (7) shall be construed as including within the
40	definition of discrimination or rebates any of the following
41	practices:

(A) Paying bonuses to policyholders or otherwise abating their



1	premiums in whole or in part out of surplus accumulated from
2	nonparticipating insurance, so long as any such bonuses or
3	abatement of premiums are fair and equitable to policyholders
4	and for the best interests of the company and its policyholders.
5	(B) In the case of life insurance policies issued on the
6	industrial debit plan, making allowance to policyholders who
7	have continuously for a specified period made premium
8	payments directly to an office of the insurer in an amount
9	which fairly represents the saving in collection expense.
10	(C) Readjustment of the rate of premium for a group insurance
11	policy based on the loss or expense experience thereunder, at
12	the end of the first year or of any subsequent year of insurance
13	thereunder, which may be made retroactive only for such
14	policy year.
15	(D) Paying by an insurer or insurance producer thereof duly
16	licensed as such under the laws of this state of money,
17	commission, or brokerage, or giving or allowing by an insurer
18	or such licensed insurance producer thereof anything of value,
19	for or on account of the solicitation or negotiation of policies
20	or other contracts of any kind or kinds, to a broker, an
21	insurance producer, or a solicitor duly licensed under the laws
22	of this state, but such broker, insurance producer, or solicitor
23	receiving such consideration shall not pay, give, or allow
24	credit for such consideration as received in whole or in part,
25	directly or indirectly, to the insured by way of rebate.
26	(9) Requiring, as a condition precedent to loaning money upon the
27	security of a mortgage upon real property, that the owner of the
28	property to whom the money is to be loaned negotiate any policy
29	of insurance covering such real property through a particular
30	insurance producer or broker or brokers. However, this
31	subdivision shall not prevent the exercise by any lender of the
32	lender's right to approve or disapprove of the insurance company
33	selected by the borrower to underwrite the insurance.
34	(10) Entering into any contract, combination in the form of a trust
35	or otherwise, or conspiracy in restraint of commerce in the
36	business of insurance.
37	(11) Monopolizing or attempting to monopolize or combining or
38	conspiring with any other person or persons to monopolize any
39	part of commerce in the business of insurance. However,

participation as a member, director, or officer in the activities of

any nonprofit organization of insurance producers or other

workers in the insurance business shall not be interpreted, in



40

41

1	itself, to constitute a combination in restraint of trade or as
2	combining to create a monopoly as provided in this subdivision
3	and subdivision (10). The enumeration in this chapter of specific
4	unfair methods of competition and unfair or deceptive acts and
5	practices in the business of insurance is not exclusive or
6	restrictive or intended to limit the powers of the commissioner or
7	department or of any court of review under section 8 of this
8	chapter.
9	(12) Requiring as a condition precedent to the sale of real or
10	personal property under any contract of sale, conditional sales
11	contract, or other similar instrument or upon the security of a
12	chattel mortgage, that the buyer of such property negotiate any
13	policy of insurance covering such property through a particular
14	insurance company, insurance producer, or broker or brokers.
15	However, this subdivision shall not prevent the exercise by any
16	seller of such property or the one making a loan thereon of the
17	right to approve or disapprove of the insurance company selected
18	by the buyer to underwrite the insurance.
19	(13) Issuing, offering, or participating in a plan to issue or offer,
20	any policy or certificate of insurance of any kind or character as
21	an inducement to the purchase of any property, real, personal, or
22	mixed, or services of any kind, where a charge to the insured is
23	not made for and on account of such policy or certificate of
24	insurance. However, this subdivision shall not apply to any of the
25	following:
26	(A) Insurance issued to credit unions or members of credit
27	unions in connection with the purchase of shares in such credit
28	unions.
29	(B) Insurance employed as a means of guaranteeing the
30	performance of goods and designed to benefit the purchasers
31	or users of such goods.
32	(C) Title insurance.
33	(D) Insurance written in connection with an indebtedness and
34	intended as a means of repaying such indebtedness in the
35	event of the death or disability of the insured.
36	(E) Insurance provided by or through motorists service clubs
37	or associations.
38	(F) Insurance that is provided to the purchaser or holder of an
39	air transportation ticket and that:
40	(i) insures against death or nonfatal injury that occurs during
41	the flight to which the ticket relates;

(ii) insures against personal injury or property damage that



occurs during travel to or from the airport in a common
carrier immediately before or after the flight;
(iii) insures against baggage loss during the flight to which
the ticket relates; or
(iv) insures against a flight cancellation to which the ticket
relates.
(14) Refusing, because of the for-profit status of a hospital or
medical facility, to make payments otherwise required to be made
under a contract or policy of insurance for charges incurred by an
insured in such a for-profit hospital or other for-profit medical
facility licensed by the state department of health.
(15) Refusing to insure an individual, refusing to continue to issue
insurance to an individual, limiting the amount, extent, or kind of
coverage available to an individual, or charging an individual a
different rate for the same coverage, solely because of that
individual's blindness or partial blindness, except where the
refusal, limitation, or rate differential is based on sound actuarial
principles or is related to actual or reasonably anticipated
experience.
(16) Committing or performing, with such frequency as to
indicate a general practice, unfair claim settlement practices (as
defined in section 4.5 of this chapter).
(17) Between policy renewal dates, unilaterally canceling an
individual's coverage under an individual or group health
insurance policy solely because of the individual's medical or
physical condition.
(18) Using a policy form or rider that would permit a cancellation
of coverage as described in subdivision (17).
(19) Violating IC 27-1-22-25, IC 27-1-22-26, or IC 27-1-22-26.1
concerning motor vehicle insurance rates.
(20) Violating IC 27-8-21-2 concerning advertisements referring
to interest rate guarantees.
(21) Violating IC 27-8-24.3 concerning insurance and health plan
coverage for victims of abuse.
(22) Violating IC 27-8-26 concerning genetic screening or testing.
(23) Violating IC 27-1-15.6-3(b) concerning licensure of
insurance producers.
(24) Violating IC 27-1-38 concerning depository institutions.
(25) Violating IC 27-8-28-17(c) or IC 27-13-10-8(c) concerning
the resolution of an appealed grievance decision.
(26) Violating IC 27-8-5-2.5(e) through IC 27-8-5-2.5(j) (expired
July 1, 2007, and removed) or IC 27-8-5-19.2 (expired July 1,



1	2007, and repealed).
2	(27) Violating IC 27-2-21 concerning use of credit information.
3	(28) Violating IC 27-4-9-3 concerning recommendations to
4	consumers.
5	(29) Engaging in dishonest or predatory insurance practices in
6	. ,
7	marketing or sales of insurance to members of the United States
	Armed Forces as:
8	(A) described in the federal Military Personnel Financial
9	Services Protection Act, P.L.109-290; or
10	(B) defined in rules adopted under subsection (b).
11	(30) Violating IC 27-8-19.8-20.1 concerning stranger originated
12	life insurance.
13	(31) Violating IC 27-2-22 concerning retained asset accounts.
14	(32) Violating IC 27-8-5-29 concerning health plans offered
15	through a health benefit exchange (as defined in IC 27-19-2-8).
16	(33) Violating a requirement of the federal Patient Protection and
17	Affordable Care Act (P.L. 111-148), as amended by the federal
18	Health Care and Education Reconciliation Act of 2010 (P.L.
19	111-152), that is enforceable by the state.
20	(34) After June 30, 2015, violating IC 27-2-23 concerning
21	unclaimed life insurance, annuity, or retained asset account
22	benefits.
23	(35) Willfully violating IC 27-1-12-46 concerning a life insurance
24	policy or certificate described in IC 27-1-12-46(a).
25	(36) Violating IC 27-1-37-7 concerning prohibiting the
26	disclosure of health care services claims data.
27	(b) Except with respect to federal insurance programs under
28	Subchapter III of Chapter 19 of Title 38 of the United States Code, the
29	commissioner may, consistent with the federal Military Personnel
30	Financial Services Protection Act (10 U.S.C. 992 note), adopt rules
31	under IC 4-22-2 to:
32	(1) define; and
33	(2) while the members are on a United States military installation
34	or elsewhere in Indiana, protect members of the United States
35	Armed Forces from;
36	dishonest or predatory insurance practices.
37	SECTION 38. IC 27-8-11-13 IS ADDED TO THE INDIANA
38	CODE AS A NEW SECTION TO READ AS FOLLOWS
39	[EFFECTIVE JANUARY 1, 2021]: Sec. 13. (a) A fully credentialed
40	provider shall be reimbursed for eligible services provided at any
41	in-network hospital if the following conditions are met:
42	(1) The provider submits the documentation required by the
	· · · · · · · · · · · · · · · · · · ·



1	insurer to be loaded under the provider group or hospital.
2	(2) The provider, provider group, or hospital is a network
3	provider with the insurer.
4	(3) The services are provided in accordance with all terms and
5	conditions of the provider's, group provider's, or hospital's
6	agreement or contract with the insurer.
7	(4) Prior authorization is obtained in accordance with
8	IC 27-1-37.5 when required by the insurer for an eligible
9	service.
0	(b) The insurer shall reimburse the provider or hospital for
11	services described in subsection (a) at the rates determined by the
12	contract between the provider and the insurer.
13	(c) An insurer is not required to credential a provider. However,
14	if:
15	(1) a provider is employed by a hospital that is part of the
16	hospital's network that is covered by the insurer; and
17	(2) the provider meets the insurer's credentialing
18	requirements;
19	the insurer shall reimburse the provider for any reimbursable
20	services from the date that the provider was employed by the
21	hospital.
22	SECTION 39. IC 27-13-43-4 IS ADDED TO THE INDIANA
23	CODE AS A NEW SECTION TO READ AS FOLLOWS
24	[EFFECTIVE JANUARY 1, 2021]: Sec. 4. (a) A fully credentialed
25	provider shall be reimbursed for eligible services provided at any
26	in-network hospital if the following conditions are met:
27	(1) The provider submits the documentation required by the
28	health maintenance organization to be loaded under the
29	provider group or hospital.
30	(2) The provider, provider group, or hospital is a network
31	provider with the health maintenance organization.
32	(3) The services are provided in accordance with all terms and
33	conditions of the provider's, group provider's, or hospital's
34	agreement or contract with the health maintenance
35	organization.
36	(4) Prior authorization is obtained in accordance with
37	IC 27-1-37.5 when required by the health maintenance
38	organization for an eligible service.
39	(b) The health maintenance organization shall reimburse the
10	provider or hospital for services described in subsection (a) at the
11	rates determined by the contract between the provider and the



42

health maintenance organization.

1	(c) A health maintenance organization is not required to
2	credential a provider. However, if:
3	(1) a provider is employed by a hospital that is part of the
4	hospital's network that is covered by the health maintenance
5	organization; and
6	(2) the provider meets the health maintenance organization's
7	credentialing requirements;
8	the health maintenance organization shall reimburse the provider
9	for any reimbursable services from the date that the provider was
10	employed by the hospital.
11	SECTION 40. IC 36-2-14-21, AS AMENDED BY P.L.1-2007,
12	SECTION 240, IS AMENDED TO READ AS FOLLOWS
13	[EFFECTIVE JULY 1, 2020]: Sec. 21. (a) As used in this section,
14	"health records" means written, electronic, or printed information
15	possessed by a provider concerning any diagnosis, treatment, or
16	prognosis of the patient. The term includes mental health records,
17	alcohol and drug abuse records, and emergency ambulance service
18	records.
19	(b) As used in this section, "provider" has the meaning set forth in
20	IC 16-18-2-295(b). IC 16-18-2-295(c).
21	(c) As part of a medical examination or autopsy conducted under
22	this chapter, a coroner may obtain a copy of the decedent's health
23	records.
24	(d) Except as provided in subsection (e), health records obtained
25	under this section are confidential.
26	(e) The coroner may provide the health records of a decedent that
27	were obtained under this section to a prosecuting attorney or law
28	enforcement agency that is investigating the individual's death. Health
29	records received from a coroner under this subsection are confidential.
30	(f) A person who receives confidential records or information under
31	this section and knowingly or intentionally discloses the records or
32	information to an unauthorized person commits a Class A

SECTION 41. An emergency is declared for this act.



33

34

misdemeanor.

COMMITTEE REPORT

Mr. Speaker: Your Committee on Public Health, to which was referred House Bill 1005, has had the same under consideration and begs leave to report the same back to the House with the recommendation that said bill be amended as follows:

Page 6, delete lines 19 through 23, begin a new paragraph and insert:

"SECTION 5. IC 16-18-2-163.6 IS ADDED TO THE INDIANA CODE AS A **NEW** SECTION TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]: **Sec. 163.6.** "Health care services", for purposes of IC 16-51-1, has the meaning set forth in IC 16-51-1-1.".

Page 6, line 26, after "163.8." insert "(a)".

Page 6, between lines 28 and 29, begin a new paragraph and insert:

"(b) "Health carrier", for purposes of IC 16-51-2, has the meaning set forth in IC 16-51-2-1.".

Page 7, delete lines 3 through 7.

Page 7, between lines 38 and 39, begin a new paragraph and insert:

"(f) "Practitioner", for purposes of IC 16-51-1, has the meaning set forth in IC 16-51-1-4.".

Page 8, between lines 40 and 41, begin a new paragraph and insert: "(f) "Provider", for purposes of IC 16-51-2, has the meaning set forth in IC 16-51-2-2."

Page 9, delete lines 4 through 40, begin a new paragraph and insert: "SECTION 17. IC 16-18-2-328.7 IS ADDED TO THE INDIANA CODE AS A **NEW** SECTION TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]: **Sec. 328.7. "Service facility location", for purposes of IC 16-51-1, has the meaning set forth in IC 16-51-1-6.**

SECTION 18. IC 16-18-2-362.1 IS ADDED TO THE INDIANA CODE AS A **NEW** SECTION TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]: **Sec. 362.1.** "**Urgent care facility**", for purposes of IC 16-24.5-1, has the meaning set forth in IC 16-24.5-1-1."

Page 10, line 19, after "estimate" insert "within three (3) business days".

Page 10, line 20, delete "or" and insert ".".

Page 10, delete lines 21 through 24.

Page 10, between lines 28 and 29, begin a new paragraph and insert:

"Sec. 0.5. Nothing in this chapter prohibits:

(1) a self-funded health benefit plan that complies with the federal Employee Retirement Income Security Act (ERISA)



of 1974 (29 U.S.C. 1001 et seq.); or

(2) a self-insurance program established to provide group health coverage as described in IC 5-10-8-7(b), or a contract for health services as described in IC 5-10-8-7(c);

from providing information requested by a practitioner or provider facility under this chapter.".

Page 10, line 33, delete "realistic, honest" and insert "reasonable".

Page 10, line 33, delete "amount" and insert "price".

Page 12, line 6, after "services" insert "ordered, scheduled, or referred by a practitioner".

Page 12, line 6, delete "the:" and insert "the purpose of:".

Page 12, line 18, after "therapists);" insert "or".

Page 12, delete line 19.

Page 12, line 20, delete "(D)" and insert "(C)".

Page 12, delete line 21.

Page 12, between lines 23 and 24, begin a new paragraph and insert:

"Sec. 8.5. As used in this chapter, "price" means the negotiated rate between the:

- (1) provider facility and practitioner; and
- (2) covered individual's health carrier.".

Page 12, line 35, delete "." and insert ", including outpatient facilities.".

Page 12, between lines 40 and 41, begin a new line block indented and insert:

"(8) An infusion center that administers intravenous medications.".

Page 12, line 41, after "not" insert ":

(1)".

Page 12, line 42, delete "recipient." and insert "recipient; or

(2) limit the authority of a legal representative of the patient.".

Page 13, line 4, delete "amount" and insert "price".

Page 13, line 7, delete "seventy-two (72) hours" and insert "three (3) business days".

Page 13, line 10, delete "charge" and insert "price".

Page 13, line 22, delete "and" and insert ",".

Page 13, line 23, delete ":" and insert ", and other persons who provide professional health services:".

Page 13, line 39, delete "amount" and insert "price".

Page 14, line 4, delete "is" and insert "and has been verified as".

Page 14, line 27, delete "or".

Page 14, line 28, after "mail;" insert "or

(3) through a mobile application;".

HB 1005—LS 6902/DI 104



Page 14, line 34, delete "charge" and insert "price".

Page 14, line 36, delete "charges" and insert "prices".

Page 14, after line 42, begin a new paragraph and insert:

"(c) A health carrier must provide a provider facility with timely information needed by the provider facility to comply with the requirements under this chapter.".

Page 15, line 2, delete "wait" and insert "check in or register".

Page 15, line 14, after "for a" insert "nonemergency".

Page 15, line 14, delete "In".

Page 15, line 15, delete "nonemergency situations, the" and insert "**The**".

Page 15, line 16, delete "72 hours." and insert "3 business days.".

Page 15, line 24, delete "at any time".

Page 15, line 25, after "for a" insert "nonemergency".

Page 15, line 26, delete "In nonemergency situations, the" and insert "**The**".

Page 15, line 27, delete "72 hours." and insert "3 business days.".

Page 15, delete lines 28 through 42.

Page 16, delete lines 1 through 25.

Page 16, line 33, delete "chapter." and insert "chapter for the following:

- (1) For as many of the seventy (70) shoppable services specified in 45 CFR 180 (as published August 9, 2019, and as subsequently amended) that are provided by the hospital or ambulatory outpatient surgical center.
- (2) In addition to the services specified in subdivision (1), the thirty (30) most common services that are provided by the hospital or ambulatory outpatient surgical center.".

Page 17, delete lines 3 through 5.

Page 17, line 6, delete "(E)" and insert "(C)".

Page 17, line 8, delete "(F)" and insert "(D)".

Page 17, line 8, delete "." and insert "without charitable assistance from the hospital or ambulatory surgical center.

(E) Self pay with charitable assistance from the hospital or ambulatory surgical center.".

Page 17, between lines 14 and 15, begin a new paragraph and insert: "SECTION 22. IC 16-24.5 IS ADDED TO THE INDIANA CODE AS A **NEW** ARTICLE TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]:

ARTICLE 24.5. OTHER HEALTH CARE FACILITIES

Chapter 1. Urgent Care Facilities

Sec. 1. (a) As used in this chapter, "urgent care facility" means



a free standing health care facility that offers episodic, walk-in care for the treatment of acute, but not life-threatening, health conditions.

- (b) The term does not include an emergency department of a hospital or a nonprofit or government operated health clinic.
- Sec. 2. (a) Not later than March 31, 2021, an urgent care facility shall post on the Internet web site of the urgent care facility pricing and other information specified in this chapter for the fifteen (15) most common services that are provided by the urgent care facility.
- (b) The following information must be included on the Internet web site by an urgent care facility for each billing code, including, if relevant, each diagnosis related group (DRG) billing code and each health care common procedure coding system (HCPCS) billing code:
 - (1) The number of services provided for the code.
 - (2) A description of the service.
 - (3) The weighted average prices paid per service per provider type for each of the following categories:
 - (A) Employer sponsored insurance.
 - (B) Individually purchased insurance.
 - (C) Medicare, including fee for service and Medicare Advantage.
 - (D) Self pay without charitable assistance from the hospital or ambulatory surgical center.
 - (E) Self pay with charitable assistance from the hospital or ambulatory surgical center.
- Sec. 3. (a) The information displayed on the Internet web site must be in an easy to read, understandable format, and include the prices for each billing code by provider type.
- (b) An urgent care facility shall update the information on the Internet web site on a quarterly basis.

SECTION 23. IC 16-51 IS ADDED TO THE INDIANA CODE AS A **NEW** ARTICLE TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]:

ARTICLE 51. HEALTH CARE REQUIREMENTS

Chapter 1. Health Care Billing

- Sec. 1. (a) As used in this chapter, "health care services" means health care related services or products rendered or sold by a provider within the scope of the provider's license or legal authorization.
 - (b) The term includes hospital, medical, surgical, dental, vision,



and pharmaceutical services or products.

- Sec. 2. As used in this chapter, "health maintenance organization" has the meaning set forth in IC 27-13-1-19.
- Sec. 3. As used in this chapter, "insurer" has the meaning set forth in IC 27-8-11-1(e).
- Sec. 4. As used in this chapter, "practitioner" means an individual or entity duly licensed or legally authorized to provide health care services.
- Sec. 5. As used in this chapter, "provider facility" means any of the following:
 - (1) A hospital.
 - (2) A skilled nursing facility.
 - (3) An end stage renal disease provider.
 - (4) A home health agency.
 - (5) A hospice organization.
 - (6) An outpatient physical therapy, occupational therapy, or speech pathology service provider.
 - (7) A comprehensive outpatient rehabilitation facility.
 - (8) A community mental health center.
 - (9) A critical access hospital.
 - (10) A federally qualified health center.
 - (11) A histocompatibility laboratory.
 - (12) An Indian health service facility.
 - (13) An organ procurement organization.
 - (14) A religious nonmedical health care institution.
 - (15) A rural health clinic.
- Sec. 6. As used in this chapter, "service facility location" means the address where the services of a provider facility or practitioner were provided. The term consists of exact address and place of service codes as required on CMS forms 1500 and 1450, including an office, on-campus location of a hospital, and off-campus location of a hospital.
- Sec. 7. (a) A provider facility or practitioner shall include the address of the service facility location in order to obtain reimbursement for a commercial claim for health care services from an insurer, health maintenance organization, employer, or other person responsible for the payment of the cost of health care services.
- (b) An insurer, health maintenance organization, employer, or other person responsible for the payment of the cost of health care services is not required to accept a bill for health care services that does not contain the service facility location.



Sec. 8. A patient is not liable for any additional payment that is the result of a practitioner or provider facility filing an incorrect form or not including the correct service facility location as required under this chapter.

Chapter 2. Centralized Credentialing

- Sec. 1. (a) As used in this chapter, "health carrier" means an entity:
 - (1) that is subject to IC 27 and the administrative rules adopted under IC 27; and
 - (2) that enters into a contract to:
 - (A) provide health care services;
 - (B) deliver health care services;
 - (C) arrange for health care services; or
 - (D) pay for or reimburse any of the costs of health care services.
 - (b) The term includes the following:
 - (1) An insurer, as defined in IC 27-1-2-3(x), that issues a policy of accident and sickness insurance, as defined in IC 27-8-5-1(a).
 - (2) A health maintenance organization, as defined in IC 27-13-1-19.
 - (3) An administrator (as defined in IC 27-1-25-1(a)) that is licensed under IC 27-1-25.
 - (4) Any other entity that provides a plan of health insurance, health benefits, or health care services.
- Sec. 2. As used in this chapter, "provider" has the meaning set forth in IC 16-18-2-295(c)(1).
- Sec. 3. (a) The department shall implement a centralized credentials verification organization and credentialing process that:
 - (1) uses a common application, as determined by provider type;
 - (2) issues a single credentialing decision applicable to all health carriers, except as determined by the department;
 - (3) recredentials and revalidates provider information not less than once every three (3) years;
 - (4) requires attestation of enrollment and credentialing information every six (6) months; and
 - (5) is certificated or accredited by the National Committee for Quality Assurance or its successor organization.
- (b) A health carrier may not require additional credentialing requirements in order to participate in a health carrier's network.



However, a health carrier may collect additional information from the provider in order to complete a contract or provider agreement.

- (c) A health carrier is not required to contract with a provider. However, if a provider is employed by a health care facility that is covered by the health carrier or in the health carrier's network and the provider meets the credentialing requirements under this chapter, the health carrier shall reimburse the provider for any reimbursable services from the date that the provider was employed by the health care facility.
- (d) A credentialed provider may be employed by multiple health care facilities.
- (e) Except when a provider's professional license is no longer valid, a credential acquired under this chapter is valid until recredentialing is required.
 - (f) An adverse action under this section is subject to IC 4-21.5.
- (g) The department may adopt rules under IC 4-22-2 to implement this section.
- (h) The department may adopt emergency rules to implement this section. However, an emergency rule adopted under this section expires the earlier of:
 - (1) one (1) year after the rule was accepted for filing under IC 4-22-2-37.1(e); or
 - (2) June 30, 2021.

This subsection expires July 1, 2021.".

Page 17, line 23, delete "realistic, honest" and insert "reasonable".

Page 17, line 23, delete "amount" and insert "price".

Page 18, line 41, after "services" insert "**ordered**, **scheduled**, **or** referred by a practitioner".

Page 19, line 11, after "therapists);" insert "or".

Page 19, delete line 12.

Page 19, line 13, delete "(D)" and insert "(C)".

Page 19, delete line 14.

Page 19, between lines 16 and 17, begin a new paragraph and insert:

"Sec. 8.5. As used in this chapter, "price" means the negotiated rate between the:

- (1) provider facility and practitioner; and
- (2) covered individual's health carrier.".

Page 19, between lines 33 and 34, begin a new line block indented and insert:

"(8) An infusion center that administers intravenous medications.".



Page 19, line 39, delete "amount" and insert "price".

Page 19, line 42, delete "seventy-two (72) hours" and insert "**three** (3) business days".

Page 20, line 2, after "total" insert "price".

Page 20, line 37, delete "or".

Page 20, line 38, after "mail;" insert "or

(3) through a mobile application;".

Page 21, line 2, delete "charge" and insert "price".

Page 21, line 4, delete "charges" and insert "prices".

Page 21, between lines 10 and 11, begin a new paragraph and insert:

"(c) A health carrier must provide a practitioner with timely information needed by the practitioner to comply with the requirements under this chapter."

Page 21, delete lines 21 through 42, begin a new paragraph and insert:

- "Sec. 16. (a) A practitioner that has ordered, scheduled, or referred the individual for a nonemergency health care service shall provide to the individual an electronic or paper copy of a written notice that states the following, or words to the same effect: "A patient may at any time ask a practitioner for an estimate of the amount the practitioner will charge for providing a nonemergency medical service. The law requires that the estimate be provided within 3 business days.".
- (b) The state department may adopt rules under IC 4-22-2 to establish requirements for practitioners to provide additional charging information under this section.".

Page 22, delete lines 1 through 2.

Page 22, line 18, after "13.5." insert "(a)".

Page 22, between lines 28 and 29, begin a new paragraph and insert:

"(b) A copy of the written notification required under this section must be signed by the client.".

Page 22, line 31, after "to" insert ":

(1)".

Page 22, line 31, after "contracts" insert "; and

(2) contracts between a provider and a pharmacy benefits manager;".

Page 22, line 32, after "renewed" insert ", including contracts that automatically renew after the expiry date,".

Page 23, delete lines 3 through 4.

Page 23, line 5, delete "2." and insert "1.".

Page 23, line 6, delete "established under section 4 of" and insert "**created under**".





Page 23, line 7, delete "3." and insert "2.".

Page 23, delete lines 24 through 31.

Page 23, line 32, delete "5." and insert "3.".

Page 24, line 36, delete "6. (a) Before May 30, 2021," and insert "4.

(a) After May 30, 2021, but before June 15, 2021,".

Page 24, line 41, delete "5" and insert "3".

Page 25, line 2, delete "forming" and insert "informing".

Page 25, line 21, delete "7." and insert "5.".

Page 25, line 37, after "carrier's" insert "reasonable".

Page 27, line 13, after "services" insert "ordered, scheduled, or referred by a practitioner".

Page 27, line 25, after "therapists);" insert "or".

Page 27, delete line 26.

Page 27, line 27, delete "(D)" and insert "(C)".

Page 27, delete line 28.

Page 27, between lines 30 and 31, begin a new paragraph and insert:

"Sec. 9.5. As used in this chapter, "price" means the negotiated rate between the:

- (1) provider facility and practitioner; and
- (2) covered individual's health carrier;

minus the amount that the health carrier will pay.".

Page 28, between lines 5 and 6, begin a new line block indented and insert:

"(8) An infusion center that administers intravenous medications.".

Page 28, line 25, after "each" insert "scheduled".

Page 28, line 29, delete "twenty-four (24) hours" and insert "**three** (3) business days".

Page 29, between lines 3 and 4, begin a new paragraph and insert:

"(f) A practitioner and provider facility must provide a health carrier with timely information needed by the health carrier to comply with the requirements under this chapter.".

Page 29, line 9, after "14." insert "(a)".

Page 29, between lines 32 and 33, begin a new paragraph and insert:

"(b) A practitioner and provider facility must provide a health carrier with timely information needed by the health carrier comply to with the requirements under this chapter."

Page 29, line 34, delete "include on the Internet web" and insert "ensure that the Internet web site includes a printed notice that:

(1) is designed, lettered, and featured on the Internet web site so as to be conspicuous to and readable by any individual with normal vision who visits the Internet web site; and



(2) states the following, or words to the same effect: "A covered individual may at any time ask the health carrier for an estimate of the amount the health carrier will pay for or reimburse to a covered individual for nonemergency health care services that have been ordered for the covered individual or the nature and extent of the ordered nonemergency health care services a covered individual is entitled to receive from the health carrier. The law requires that an estimate be provided within 3 business days."."

Page 29, delete lines 35 through 42.

Page 30, delete lines 1 through 4.

Renumber all SECTIONS consecutively.

and when so amended that said bill do pass.

(Reference is to HB 1005 as introduced.)

KIRCHHOFER

Committee Vote: yeas 8, nays 0.

HOUSE MOTION

Mr. Speaker: I move that House Bill 1005 be amended to read as follows:

Page 6, line 25, delete "(a)".

Page 6, delete lines 28 through 29.

Page 8, delete lines 39 through 40.

Page 18, delete lines 25 through 42.

Delete page 19.

Page 20, delete lines 1 through 3.

Page 40, between lines 6 and 7, begin a new paragraph and insert: "SECTION 29. IC 27-8-11-13 IS ADDED TO THE INDIANA CODE AS A **NEW** SECTION TO READ AS FOLLOWS [EFFECTIVE JANUARY 1, 2021]: **Sec. 13. (a) A fully credentialed provider shall be reimbursed for eligible services provided at any in-network hospital if the following conditions are met:**

- (1) The provider submits the documentation required by the insurer to be loaded under the provider group or hospital.
- (2) The provider, provider group, or hospital is a network provider with the insurer.
- (3) The services are provided in accordance with all terms and



- conditions of the provider's, group provider's, or hospital's agreement or contract with the insurer.
- (4) Prior authorization is obtained in accordance with IC 27-1-37.5 when required by the insurer for an eligible service.
- (b) The insurer shall reimburse the provider or hospital for services described in subsection (a) at the rates determined by the contract between the provider and the insurer.
- (c) An insurer is not required to credential a provider. However, if:
 - (1) a provider is employed by a hospital that is part of the hospital's network that is covered by the insurer; and
 - (2) the provider meets the insurer's credentialing requirements;

the insurer shall reimburse the provider for any reimbursable services from the date that the provider was employed by the hospital.

SECTION 30. IC 27-13-43-4 IS ADDED TO THE INDIANA CODE AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JANUARY 1, 2021]: Sec. 4. (a) A fully credentialed PROVIDER shall be reimbursed for eligible services provided at any in-network hospital if the following conditions are met:

- (1) The provider submits the documentation required by the health maintenance organization to be loaded under the provider group or hospital.
- (2) The provider, provider group, or hospital is a network provider with the health maintenance organization.
- (3) The services are provided in accordance with all terms and conditions of the provider's, group provider's, or hospital's agreement or contract with the health maintenance organization.
- (4) Prior authorization is obtained in accordance with IC 27-1-37.5 when required by the health maintenance organization for an eligible service.
- (b) The health maintenance organization shall reimburse the provider or hospital for services described in subsection (a) at the rates determined by the contract between the provider and the health maintenance organization.
- (c) A health maintenance organization is not required to credential a provider. However, if:
 - (1) a provider is employed by a hospital that is part of the hospital's network that is covered by the health maintenance



organization; and

(2) the provider meets the health maintenance organization's credentialing requirements;

the health maintenance organization shall reimburse the provider for any reimbursable services from the date that the provider was employed by the hospital.".

Renumber all SECTIONS consecutively.

(Reference is to HB 1005 as printed January 24, 2020.)

LEHMAN

HOUSE MOTION

Mr. Speaker: I move that House Bill 1005 be amended to read as follows:

Page 6, between lines 8 and 9, begin a new paragraph and insert: "SECTION 3. IC 16-18-2-46.5 IS ADDED TO THE INDIANA CODE AS A **NEW** SECTION TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]: **Sec. 46.5.** "Canadian supplier", for purposes of IC 16-47-3, has the meaning set forth in IC 16-47-3-1.".

Page 7, between lines 36 and 37, begin a new paragraph and insert: "SECTION 15. IC 16-18-2-294.5, AS AMENDED BY P.L.208-2015, SECTION 4, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]: Sec. 294.5. (a) "Program", for purposes of IC 16-40-4, has the meaning set forth in IC 16-40-4-3.

- (b) "Program", for purposes of IC 16-41-7.5, has the meaning set forth in IC 16-41-7.5-2.
- (c) "Program", for purposes of IC 16-47-1, has the meaning set forth in IC 16-47-1-3.
- (d) "Program", for purposes of IC 16-47-3, has the meaning set forth in IC 16-47-3-2.".

Page 9, between lines 8 and 9, begin a new paragraph and insert: "SECTION 17. IC 16-18-2-353.3 IS ADDED TO THE INDIANA CODE AS A **NEW** SECTION TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]: **Sec. 353.3. "Track-and-trace", for purposes of IC 16-47-3, has the meaning set forth in IC 16-47-3-3."**

Page 9, between lines 13 and 14, begin a new paragraph and insert: "SECTION 19. IC 16-18-2-363.5 IS ADDED TO THE INDIANA CODE AS A **NEW** SECTION TO READ AS FOLLOWS



[EFFECTIVE JULY 1, 2020]: Sec. 363.5. "Vendor", for purposes of IC 16-47-3, has the meaning set forth in IC 16-47-3-4.".

Page 17, between lines 10 and 11, begin a new paragraph and insert: "SECTION 24. IC 16-47-3 IS ADDED TO THE INDIANA CODE AS A **NEW** CHAPTER TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]:

Chapter 3. Importation of Prescription Drugs Program

Sec. 1. As used in this chapter, "Canadian supplier" means a:

- (1) manufacturer;
- (2) wholesale drug distributor; or
- (3) pharmacy;

appropriately licensed or permitted under Canadian law to manufacture, distribute, or dispense prescription drugs.

- Sec. 2. As used in this chapter, "program" refers to the importation of prescription drugs program established by section 5 of this chapter.
- Sec. 3. As used in this chapter, "track-and-trace" means the product-tracing process for the components of the pharmaceutical distribution supply chain, as described in Title II of the federal Drug Quality and Security Act (21 U.S.C. 351 et seq.).
- Sec. 4. As used in this chapter, "vendor" means an entity that contracts with the state department to manage specified functions of the program.
- Sec. 5. (a) The importation of prescription drugs program is established.
 - (b) The state department shall administer the program.
- (c) The state department shall contract with a vendor to provide services under the program. The vendor must comply with the requirements of this chapter.
- (d) The state department shall require a bond from the vendor to mitigate the financial consequences of potential acts of malfeasance or misfeasance, potential fraudulent acts, or potential dishonest acts committed by the vendor, an employee of the vendor, or a contractor or subcontractor of the vendor.
- (e) Before July 1, 2021, the state department shall apply to the United States Department of Health and Human Services for approval of the program under 21 U.S.C. 384(1). The state department shall implement the program not later than six (6) months after the state department receives approval for the program. The request must include the following:
 - (1) A description of the state department's plan for operating the program.



- (2) A demonstration of how the prescription drugs imported into Indiana under the program will meet the applicable federal and state standards for safety and effectiveness.
- (3) A demonstration of how the prescription drugs imported into Indiana under the program will comply with federal track-and-trace procedures.
- (4) A list of proposed prescription drugs that have the highest potential for cost savings to the state through importation at the time that the request is submitted.
- (5) An estimate of the total cost savings attributable to the program.
- (6) The costs of program implementation to the state.
- (7) A list of potential Canadian suppliers from which the state would import the prescription drugs and a demonstration that the suppliers are in full compliance with relevant Canadian federal and provincial laws and regulations, as well as all applicable federal and state laws and regulations.
- (f) Upon receipt of federal approval of the program, the state department shall notify the following:
 - (1) The speaker of the house of representatives.
 - (2) The president pro tempore of the senate.
 - (3) The members of the health and provider services committee in the senate.
 - (4) The members of the public health committee in the house of representatives.
- (g) Before the start of the general assembly session following receipt of the federal approval, the state department shall submit to the individuals described in subsection (f) a proposal for the implementation of funding of the program.
- Sec. 6. (a) Before December 1, 2020, and by December 1 of each subsequent year, the vendor shall develop a wholesale prescription drug importation list identifying the prescription drugs that have the highest potential for cost savings to the state.
- (b) In developing the list, the vendor shall consider at least the following in determining whether a prescription drug should be included on the list:
 - (1) Prescription drugs that, if included on the list, would provide the highest potential for cost savings in state administered programs.
 - (2) Prescription drugs for which there is a shortage in Indiana or the United States.
 - (3) Specialty prescription drugs.



- (4) High volume prescription drugs.
- (c) The state department shall review the wholesale prescription drug importation list at least every three (3) months to ensure that the list continues to meet the requirements of the program. The state department may direct the vendor to revise the list as necessary.
 - Sec. 7. (a) The vendor shall identify Canadian suppliers that:
 - (1) are in full compliance with:
 - (A) relevant Canadian federal and provincial laws and regulations; and
 - (B) the federal Drug Quality and Security Act;
 - (2) have agreed to export prescription drugs identified on the list described in section 6 of this chapter at prices that will provide cost savings to the state; and
 - (3) have obtained an international export pharmacy permit under IC 25-26-14.5.
- (b) The vendor must verify that the Canadian suppliers meet all of the requirements of the program while meeting or exceeding the federal and state track-and-trace laws and regulations.
 - (c) The vendor shall:
 - (1) contract with an eligible Canadian supplier; or
 - (2) facilitate contracts between eligible importers and Canadian suppliers;
- to import drugs under the program.
- (d) The vendor shall maintain a list of all registered importers that participate in the program.
- (e) The vendor shall ensure compliance with Title II of the federal Drug Quality and Security Act by all suppliers, importers, distributors, and participants in the program.
- Sec. 8. (a) The vendor shall provide to the state department the following:
 - (1) An annual financial audit of the vendor's operations.
 - (2) Quarterly financial reports specific to the program, including information on the performance of the vendor and the vendor's subcontractors for the program.
- (b) The state department shall determine the format and contents of the reports described in this section.
- Sec. 9. (a) A Canadian supplier is eligible to participate in the program if the Canadian supplier meets the following requirements:
 - (1) Is in full compliance with relevant Canadian federal and provincial laws and regulations.



- (2) Is identified by the vendor as eligible to participate in the program.
- (3) Submits an attestation that the supplier has a registered agent in the United States, including the name and United States business address of the registered agent.
- (b) An importer that meets the requirements of this chapter may import a prescription drug from an eligible Canadian supplier if the following conditions are met:
 - (1) The prescription drug meets the United States Food and Drug Administration's standards concerning safety, effectiveness, misbranding, and adulteration.
 - (2) The importation of the drug would not violate federal patent laws.
 - (3) The importation of the drug is expected to generate cost savings to the state.
 - (4) The drug is not any of the following:
 - (A) A controlled substance.
 - (B) A biological product.
 - (C) An infused drug.
 - (D) An intravenously injected drug.
 - (E) A drug that is inhaled during surgery.
 - (F) A drug that is a parenteral drug, the importation of which is determined by the United States Secretary of Health and Human Services to pose a threat to the public health.
- Sec. 10. (a) The following entities may import prescription drugs under the program from a Canadian supplier that meets the requirements of this chapter:
 - (1) A pharmacist or wholesale drug distributor employed by or under contract with the state department for distribution to a county health department for dispensing to the patients of the county health department.
 - (2) A pharmacist or wholesale drug distributor employed by or under contract with a pharmacy that is a Medicaid provider, for dispensing to the pharmacy's Medicaid recipients.
 - (3) A pharmacist or wholesale drug distributor employed by or under contract with the department of correction, for dispensing to inmates in the custody of the department of correction.
- (b) A Canadian supplier that meets the requirements of this chapter and an eligible importer described in subsection (a) that is



participating in the program:

- (1) must comply with all track-and-trace requirements; and
- (2) may not distribute, dispense, or sell prescription drugs imported under this program outside Indiana.
- Sec. 11. (a) The vendor shall ensure the safety and quality of drugs imported under the program.
 - (b) The vendor shall do the following:
 - (1) For an initial imported shipment of a specific drug by an importer, ensure that each batch of the drug in the shipment is statistically sampled and tested for authenticity and degradation in a manner consistent with federal law.
 - (2) For every subsequent imported shipment of that drug by that importer, ensure that a statistically valid sample of the shipment is tested for authenticity and degradation in a manner consistent with federal law.
 - (3) Certify that the drug:
 - (A) is approved for marketing in the United States and is not adulterated or misbranded; and
 - (B) meets all of the labeling requirements under 21 U.S.C. 352.
 - (4) Maintain qualified laboratory records, including complete data derived from all tests necessary to ensure that the drug is in compliance with the requirements of this section.
 - (5) Maintain documentation demonstrating that the testing required by this section was conducted at a qualified laboratory in accordance with federal and state laws and regulations governing laboratory qualifications.
- (c) All testing required by this section must be conducted in a qualified laboratory that meets the standards under federal and state laws and regulations governing laboratory qualifications for drug testing.
- (d) The vendor shall maintain information and documentation submitted under this section for at least seven (7) years.
- Sec. 12. An importer participating in the program must submit all of the following information to the vendor concerning drugs provided for the program:
 - (1) The name and quantity of the active ingredients of the drug.
 - (2) A description of the dosage form of the drug.
 - (3) The date on which the drug is received.
 - (4) The quantity of the drug that is received.
 - (5) The point of origin and destination of the drug.



- (6) The price paid by the importer for the drug.
- Sec. 13. (a) A Canadian supplier participating in the program must submit the following information and documentation to the vendor specifying all of the following concerning drugs provided for the program:
 - (1) The original source of the drug, including:
 - (A) the name of the manufacturer of the drug;
 - (B) the date on which the drug was manufactured; and
 - (C) the location, including the country, state or province, and city, where the drug was manufactured.
 - (2) The date on which the drug is shipped.
 - (3) The quantity of the drug that is shipped.
 - (4) The quantity of each lot of the drug originally received and the source of the lot.
 - (5) The lot or control number and the batch number assigned to the drug by the manufacturer.
- (b) The state department may require that the vendor collect additional information from the Canadian supplier that is necessary to ensure the protection of the public health.
- Sec. 14. (a) The state department shall immediately suspend the importation of a specific drug or the importation of drugs by a specific importer if the state department discovers that any drug or importer activity is in violation of this chapter or any federal or state law or regulation.
- (b) The state department may revoke the suspension under subsection (a) of the importation of a specific drug or the importation of drugs by a specific importer if the state department determines that the public is adequately protected from counterfeit or unsafe drugs being imported into Indiana.
- Sec. 15. Before December 1 of each year, the state department shall submit a report to the governor and the general assembly in an electronic format under IC 5-14-6 on the operation of the program during the previous fiscal year. The report must include at least the following:
 - (1) A list of the prescription drugs that were imported under the program.
 - (2) The number of participating persons.
 - (3) The number of prescriptions dispensed through the program.
 - (4) The estimated cost savings to the state during the previous fiscal year and to date that are attributable to the program.
 - (5) A description of the methodology used to determine which



drugs should be included on the wholesale prescription drug importation list.

- (6) Documentation on how the program ensures the following:
 - (A) Canadian suppliers participating in the program are of high quality and high performance and in full compliance with relevant:
 - (i) Canadian federal and provincial laws and regulations; and
 - (ii) federal and state laws, regulations, and rules.
 - (B) Prescription drugs imported under the program are not shipped, sold, or dispensed outside Indiana once in the possession of the importer.
 - (C) Prescription drugs imported under the program are pure, unadulterated, potent, and safe.
 - (D) The program does not place consumers at a higher health and safety risk than if the consumers did not participate.
 - (E) The program provides cost savings to the state on imported prescription drugs.
- Sec. 16. The state department shall adopt rules under IC 4-22-2 necessary to implement this chapter."

Page 24, after line 42, begin a new paragraph and insert:

"SECTION 26. IC 25-26-13-4, AS AMENDED BY P.L.5-2016, SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]: Sec. 4. (a) The board may:

- (1) adopt rules under IC 4-22-2 for implementing and enforcing this chapter;
- (2) establish requirements and tests to determine the moral, physical, intellectual, educational, scientific, technical, and professional qualifications for applicants for pharmacists' licenses:
- (3) refuse to issue, deny, suspend, or revoke a license or permit or place on probation or fine any licensee or permittee under this chapter:
- (4) regulate the sale of drugs and devices in the state of Indiana;
- (5) impound, embargo, confiscate, or otherwise prevent from disposition any drugs, medicines, chemicals, poisons, or devices which by inspection are deemed unfit for use or would be dangerous to the health and welfare of the citizens of the state of Indiana; the board shall follow those embargo procedures found in IC 16-42-1-18 through IC 16-42-1-31, and persons may not refuse to permit or otherwise prevent members of the board or



- their representatives from entering such places and making such inspections;
- (6) prescribe minimum standards with respect to physical characteristics of pharmacies, as may be necessary to the maintenance of professional surroundings and to the protection of the safety and welfare of the public;
- (7) subject to IC 25-1-7, investigate complaints, subpoena witnesses, schedule and conduct hearings on behalf of the public interest on any matter under the jurisdiction of the board;
- (8) prescribe the time, place, method, manner, scope, and subjects of licensing examinations which shall be given at least twice annually; and
- (9) perform such other duties and functions and exercise such other powers as may be necessary to implement and enforce this chapter.
- (b) The board shall adopt rules under IC 4-22-2 for the following:
 - (1) Establishing standards for the competent practice of pharmacy.
 - (2) Establishing the standards for a pharmacist to counsel individuals regarding the proper use of drugs.
 - (3) Establishing standards and procedures before January 1, 2006, to ensure that a pharmacist:
 - (A) has entered into a contract that accepts the return of expired drugs with; or
 - (B) is subject to a policy that accepts the return of expired drugs of;
 - a wholesaler, manufacturer, or agent of a wholesaler or manufacturer concerning the return by the pharmacist to the wholesaler, the manufacturer, or the agent of expired legend drugs or controlled drugs. In determining the standards and procedures, the board may not interfere with negotiated terms related to cost, expenses, or reimbursement charges contained in contracts between parties, but may consider what is a reasonable quantity of a drug to be purchased by a pharmacy. The standards and procedures do not apply to vaccines that prevent influenza, medicine used for the treatment of malignant hyperthermia, and other drugs determined by the board to not be subject to a return policy. An agent of a wholesaler or manufacturer must be appointed in writing and have policies, personnel, and facilities to handle properly returns of expired legend drugs and controlled substances.
 - (4) The following concerning the issuance of a permit under



IC 25-26-14.5:

- (A) Inspection report requirements described under IC 25-26-14.5-1.
- (B) The financial responsibility of entities that hold any permit under IC 25-26-14.5.
- (c) The board may grant or deny a temporary variance to a rule it has adopted if:
 - (1) the board has adopted rules which set forth the procedures and standards governing the grant or denial of a temporary variance; and
 - (2) the board sets forth in writing the reasons for a grant or denial of a temporary variance.
- (d) The board shall adopt rules and procedures, in consultation with the medical licensing board, concerning the electronic transmission of prescriptions. The rules adopted under this subsection must address the following:
 - (1) Privacy protection for the practitioner and the practitioner's patient.
 - (2) Security of the electronic transmission.
 - (3) A process for approving electronic data intermediaries for the electronic transmission of prescriptions.
 - (4) Use of a practitioner's United States Drug Enforcement Agency registration number.
 - (5) Protection of the practitioner from identity theft or fraudulent use of the practitioner's prescribing authority.
 - (e) The governor may direct the board to develop:
 - (1) a prescription drug program that includes the establishment of criteria to eliminate or significantly reduce prescription fraud; and
 - (2) a standard format for an official tamper resistant prescription drug form for prescriptions (as defined in IC 16-42-19-7(1)).

The board may adopt rules under IC 4-22-2 necessary to implement this subsection.

- (f) The standard format for a prescription drug form described in subsection (e)(2) must include the following:
 - (1) A counterfeit protection bar code with human readable representation of the data in the bar code.
 - (2) A thermochromic mark on the front and the back of the prescription that:
 - (A) is at least one-fourth (1/4) of one (1) inch in height and width; and
 - (B) changes from blue to clear when exposed to heat.
 - (g) The board may contract with a supplier to implement and



manage the prescription drug program described in subsection (e). The supplier must:

- (1) have been audited by a third party auditor using the SAS 70 audit or an equivalent audit for at least the three (3) previous years; and
- (2) be audited by a third party auditor using the SAS 70 audit or an equivalent audit throughout the duration of the contract;

in order to be considered to implement and manage the program.

- (h) The board shall adopt rules under IC 4-22-2, or emergency rules in the manner provided under IC 4-22-2-37.1 that take effect on July 1, 2016, concerning:
 - (1) professional determinations made under IC 35-48-4-14.7(d); and
 - (2) the determination of a relationship on record with the pharmacy under IC 35-48-4-14.7.
 - (i) The board may:
 - (1) review professional determinations made by a pharmacist; and
 - (2) take appropriate disciplinary action against a pharmacist who violates a rule adopted under subsection (h) concerning a professional determination made;

under IC 35-48-4-14.7 concerning the sale of ephedrine and pseudoephedrine.

SECTION 27. IC 25-26-13-29, AS AMENDED BY P.L.209-2018, SECTION 10, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]: Sec. 29. (a) It is unlawful:

- (1) For any person to display or permit to be displayed, a pharmacy permit in any facility or place of business other than that for which it was issued.
- (2) For any person to accept a prescription for filling or compounding at any place or facility for which there is not a valid pharmacy permit.
- (3) For any person to operate a pharmacy or to take, assume, exhibit, display, or advertise by any medium, the title "drugs", "prescriptions", "medicine", "drug store", "pharmacy", or "apothecary shop", or any combination of such titles or any other title, symbol, term, or description of like import intended to cause the public to believe that it is a pharmacy unless the person holds a valid pharmacy permit.
- (4) For any person to engage or offer to engage in the practice of pharmacy or to hold himself or herself out as a pharmacist without a valid pharmacist's license that is classified as active by the board.



- (b) A person who violates a provision of subsection (a) commits a Level 6 felony.
- (c) Nothing in this chapter shall apply to, nor in any manner interfere with the business of a general merchant in selling and distributing nonnarcotic, nonprescription medicines or drugs which are prepackaged, fully prepared by the manufacturer for use by the consumer, and labeled in accordance with the requirements of the state and federal food and drug acts.
- (d) This chapter does not apply to, or in any manner interfere with, the business of a manufacturer in selling and delivering a dialysate drug or a device that is necessary for home peritoneal renal dialysis for a patient who has end stage renal disease if all of the following apply:
 - (1) The dialysate drug or device is approved by the federal Food and Drug Administration under federal law.
 - (2) The dialysate drug or device is held by the manufacturer, a third party logistics provider, or a wholesale drug distributor in accordance with the requirements of IC 25-26-14.
 - (3) The dialysate drug or device is delivered in the manufacturer's original, sealed packaging.
 - (4) The dialysate drug or device is delivered only upon:
 - (A) receipt of a physician's prescription by a pharmacy that holds a pharmacy permit under this chapter; and
 - (B) the transmittal of an order from the pharmacy described in clause (A) to the manufacturer, third party logistics provider, or wholesale drug distributor.
 - (5) The manufacturer, third party logistics provider, or wholesale drug distributor delivers the dialysate drug or device directly to:
 - (A) the patient or the patient's designee for self-administration of the dialysis therapy; or
 - (B) a health care provider for administration of the dialysis therapy to the patient.
- (e) This chapter does not apply to the purchase of prescription drugs through and in compliance with the importation of prescription drugs program established under IC 16-47-3.

SECTION 28. IC 25-26-14-17.8, AS AMENDED BY P.L.98-2006, SECTION 22, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]: Sec. 17.8. (a) **This section does not apply to purchase of prescription drugs through and in compliance with the importation of prescription drugs program established under IC 16-47-3.** A wholesale drug distributor licensed under this chapter that purchases legend drugs from a wholesale drug distributor that is not licensed under this chapter shall act with due diligence as required



under this section and rules adopted by the board. However, the due diligence requirements of this section do not apply to purchases from an unlicensed wholesale drug distributor that has obtained accreditation through the National Association of Boards of Pharmacy's Verified-Accredited Wholesale Distributors program.

- (b) Before the initial purchase of legend drugs from the unlicensed wholesale drug distributor, the licensed wholesale drug distributor shall obtain the following information from the unlicensed wholesale drug distributor:
 - (1) A list of states in which the unlicensed wholesale drug distributor is licensed.
 - (2) A list of states into which the unlicensed wholesale drug distributor ships legend drugs.
 - (3) Copies of all state and federal regulatory licenses and registrations held by the unlicensed wholesale drug distributor.
 - (4) The unlicensed wholesale drug distributor's most recent facility inspection reports.
 - (5) Information regarding general and product liability insurance maintained by the unlicensed wholesale drug distributor, including copies of relevant policies.
 - (6) A list of other names under which the unlicensed wholesale drug distributor does business or has been previously known.
 - (7) A list of corporate officers and managerial employees of the unlicensed wholesale drug distributor.
 - (8) A list of all owners of the unlicensed wholesale drug distributor that own more than ten percent (10%) of the unlicensed wholesale drug distributor, unless the unlicensed wholesale drug distributor is publicly traded.
 - (9) A list of all disciplinary actions taken against the unlicensed wholesale drug distributor by state and federal agencies.
 - (10) A description, including the address, dimensions, and other relevant information, of each facility used by the unlicensed wholesale drug distributor for legend drug storage and distribution.
 - (11) A description of legend drug import and export activities of the unlicensed wholesale drug distributor.
 - (12) A description of the unlicensed wholesale drug distributor's procedures to ensure compliance with this chapter.
 - (13) A statement:
 - (A) as to whether; and
 - (B) of the identity of each manufacturer for which; the unlicensed wholesale drug distributor is an authorized



distributor.

- (c) Before the initial purchase of legend drugs from an unlicensed wholesale drug distributor, the licensed wholesale drug distributor shall:
 - (1) request that the board obtain and consider the results of a national criminal history background check (as defined in IC 10-13-3-12) through the state police department of all individuals associated with the unlicensed wholesale drug distributor as specified for licensure of a wholesale drug distributor under section 16(b) of this chapter; and
 - (2) verify the unlicensed wholesale drug distributor's status as an authorized distributor, if applicable.
- (d) If an unlicensed wholesale drug distributor's facility has not been inspected by the board or the board's agent within three (3) years after a contemplated purchase described in subsection (a), the licensed wholesale drug distributor shall conduct an inspection of the unlicensed wholesale drug distributor's facility:
 - (1) before the initial purchase of legend drugs from the unlicensed wholesale drug distributor; and
 - (2) at least once every three (3) years unless the unlicensed wholesale drug distributor's facility has been inspected by the board, or the board's agent, during the same period;

to ensure compliance with applicable laws and regulations relating to the storage and handling of legend drugs. A third party may be engaged to conduct the site inspection on behalf of the licensed wholesale drug distributor.

- (e) At least annually, a licensed wholesale drug distributor that purchases legend drugs from an unlicensed wholesale drug distributor shall ensure that the unlicensed wholesale drug distributor maintains a record keeping system that meets the requirements of section 17(3) of this chapter.
- (f) If a licensed wholesale drug distributor that purchases legend drugs from an unlicensed wholesale drug distributor has reason to believe that a legend drug purchased from the unlicensed wholesale drug distributor is misbranded, adulterated, counterfeit, or suspected counterfeit, the licensed wholesale drug distributor shall conduct a for cause authentication of each distribution of the legend drug back to the manufacturer.
- (g) An unlicensed wholesale drug distributor that has engaged in the distribution of a legend drug for which a licensed wholesale drug distributor conducts a for cause authentication under subsection (f) shall provide, upon request, detailed information regarding the



distribution of the legend drug, including the:

- (1) date of purchase of the legend drug;
- (2) lot number of the legend drug;
- (3) sales invoice number of the legend drug; and
- (4) contact information, including name, address, telephone number, and any electronic mail address of the unlicensed wholesale drug distributor that sold the legend drug.
- (h) If a licensed wholesale drug distributor conducts a for cause authentication under subsection (f) and is unable to authenticate each distribution of the legend drug, the licensed wholesale drug distributor shall quarantine the legend drug and report the circumstances to the board and the federal Food and Drug Administration within ten (10) business days after completing the attempted authentication.
- (i) If a licensed wholesale drug distributor authenticates the distribution of a legend drug back to the manufacturer under subsection (f), the licensed wholesale drug distributor shall maintain records of the authentication for three (3) years and shall provide the records to the board upon request.
- (j) A licensed wholesale drug distributor that purchases legend drugs from an unlicensed wholesale drug distributor shall, at least annually, conduct random authentications of required pedigrees on at least ten percent (10%) of sales units of distributions of legend drugs that were purchased from unlicensed wholesale drug distributors.
- (k) An unlicensed wholesale drug distributor from which a licensed wholesale drug distributor has purchased legend drugs shall cooperate with the random authentications of pedigrees under this section and provide requested information in a timely manner.
- (l) If a wholesale drug distributor conducts a random authentication under subsection (j) and is unable to authenticate each distribution of the legend drug, the wholesale drug distributor shall quarantine the legend drug and report the circumstances to the board and the federal Food and Drug Administration not more than ten (10) business days after completing the attempted authentication.

SECTION 29. IC 25-26-14.5 IS ADDED TO THE INDIANA CODE AS A **NEW** CHAPTER TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2020]:

Chapter 14.5. International Export Pharmacy Permit and Wholesale Drug Distributor Permit

Sec. 1. (a) To participate as an exporter of prescription drugs into Indiana under the importation of prescription drugs program established by IC 16-47-3-5, a pharmacy located outside the United States must meet the following requirements:



- (1) Hold an international export pharmacy permit issued under this chapter.
- (2) Maintain at all times an active and unencumbered license or permit to operate a pharmacy:
 - (A) in compliance with the laws and rules of the jurisdiction in which the pharmacy is located and from which the prescription drugs will be exported; and
 - (B) in a country with which the United States has a current mutual recognition agreement, cooperation agreement, memorandum of understanding, or other federal mechanism recognizing the country's adherence to current good manufacturing practices for pharmaceutical products.
- (3) Submit an application for an international export pharmacy permit on a form developed and provided by the board.
- (b) An applicant for an international export pharmacy permit must submit the following to the board with the application required under subsection (a)(3):
 - (1) Proof of an active and unencumbered license or permit to operate a pharmacy in compliance with the laws and rules of the jurisdiction in which the dispensing facility is located and from which the prescription drugs will be exported.
 - (2) Documentation demonstrating that the country in which the pharmacy operates has a current mutual recognition agreement, cooperation agreement, memorandum of understanding, or other federal mechanism recognizing the country's adherence to current good manufacturing practices for pharmaceutical products.
 - (3) The location, names, and title of all principal corporate officers and the pharmacist who serves as the prescription department manager for prescription drugs exported into Indiana under the importation of prescription drugs program.
 - (4) A written attestation by an owner or officer of the applicant and by the applicant's prescription drug manager containing the following affirmations:
 - (A) That the individual has read and understands the laws and rules governing the manufacture, distribution, and dispensing of prescription drugs in Indiana.
 - (B) That prescription drugs shipped, mailed, or delivered into Indiana:
 - (i) will meet or exceed Indiana's standards for safety and



efficacy; and

- (ii) will not have been, and may not be, manufactured or distributed in violation of the laws and rules of the jurisdiction in which the applicant is located and from which the prescription drugs will be exported.
- (5) A current inspection report from an inspection conducted by the regulatory or licensing agency of the jurisdiction in which the applicant is located. The inspection report must reflect compliance with this section. An inspection report is current if the inspection was conducted not earlier than $\sin(6)$ months before the submission of the application for an initial permit or not earlier than one (1) year for the renewal of a permit.
- (c) If an applicant is not able to submit an inspection report that meets the requirements of subsection (b)(5), the board must do one (1) of the following:
 - (1) Conduct, or contract with a person to conduct, an onsite inspection at the cost of the applicant.
 - (2) Accept a current inspection report from an entity that:
 - (A) meets requirements adopted by the board under IC 4-22-2 for entities to perform inspections; and
 - (B) has been approved by the board.
 - (3) Accept a current inspection report from the United States Food and Drug Administration conducted under the federal Drug Quality and Security Act.
- Sec. 2. To participate as an exporter of prescription drugs into Indiana under the importation of prescription drugs program established by IC 16-47-3, a nonresident prescription drug manufacturer located outside the United States must register with the board and obtain the international export pharmacy permit under this chapter.
- Sec. 3. (a) The board shall adopt rules under IC 4-22-2 governing the financial responsibility of a pharmacy that holds a permit under this chapter. The rules must include at least the following:
 - (1) Financial reporting requirements.
 - (2) Standards for financial capability to perform the functions governed by the permit.
 - (3) Requirements for ensuring that the permit holder and the permit holder's contractors can be held accountable for the financial consequences of any act of malfeasance or misfeasance or fraudulent or dishonest acts committed by the



permit holder or the permit holder's contractors.

- (b) The board shall adopt rules under IC 4-22-2 concerning inspection report requirements described in section 1 of this chapter.
- Sec. 4. (a) A wholesale drug distributor located outside the United States must obtain an international prescription drug wholesale drug distributor permit under this chapter to engage in the wholesale exportation and distribution of prescription drugs in Indiana under the importation of prescription drugs program established by IC 16-47-3-5.
- (b) A wholesale drug distributor must meet the following in order to obtain a wholesale drug distributor permit:
 - (1) Be licensed or permitted to operate in a country with which the United States has:
 - (A) a current mutual recognition agreement;
 - (B) a current cooperation agreement;
 - (C) a current memorandum of understanding; or
 - (D) another federal mechanism recognizing the country's adherence to current good manufacturing practices for pharmaceutical products.
 - (2) Maintain at all times a license or permit to engage in the wholesale distribution of prescription drugs in compliance with the laws and rules of the jurisdiction in which the wholesale drug distributor operates.
- (c) The board shall adopt rules under IC 4-22-2 governing the financial responsibility of a wholesale drug distributor that holds a permit under this chapter. The rules must include at least the following:
 - (1) Financial reporting requirements.
 - (2) Standards for financial capability to perform the functions governed by the permit.
 - (3) Requirements for ensuring that a wholesale drug distributor holding a permit under this chapter and the wholesale drug distributor's contractors are held accountable for the financial consequences of any act of malfeasance or misfeasance or fraudulent or dishonest acts committed by the permit holder or the permit holder's contractors."

Renumber all SECTIONS consecutively.

(Reference is to HB 1005 as printed January 24, 2020.)

HATFIELD

